前列腺癌临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 3

NCI NCT04423211 / NCI-2020-02686

Treating Prostate Cancer That Has Come Back after Surgery with Apalutamide and Targeted Radiation Based on PET Imaging, INDICATE Trial

AI 简述这是一项III期试验，研究Apalutamide联合PET指导的靶向放疗用于术后生化复发的前列腺癌。

?

适用疾病: Stage IVB Prostate Cancer；Biochemically Recurrent Prostate Carcinoma；Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: ECOG-ACRIN Cancer Research Group

正在招募 Phase 3

NCI NCT06235697 / NCI-2023-09091

A Study of Two Different Radiotherapy Treatment Strategies Given with Hormone Therapy for Participants with Unfavorable-Risk, Localized Prostate Cancer, ASCENDE-SBRT Trial

AI 简述这是一项3期试验，比较两种不同放疗策略联合激素疗法用于中危局限性前列腺癌。

?

适用疾病: Stage II Prostate Cancer；Stage III Prostate Cancer；Localized Prostate Adenocarcinoma
干预: 未列出
地点: United States，Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 3

NCI NCT06112990 / NCI-2023-09483

Creatine Supplementation in Combination with Resistance Training for Preserving Muscle Mass and Improving Outcomes in Patients with Metastatic Prostate Cancer, The Creatine-52 Trial

AI 简述这是一项III期试验，研究肌酸补充联合抗阻训练用于转移性前列腺癌患者。

?

适用疾病: Stage IVB Prostate Cancer；Castration-Sensitive Prostate Carcinoma；Metastatic Prostate Cancer
干预: 未列出
地点: United States
申办方: Huntsman Cancer Institute/University of Utah

正在招募 Phase 3

NCI NCT06205316 / NCI-2023-10897

Stereotactic Body Radiation Therapy Compared to Hypofractionated Radiation Therapy for the Treatment of Patients with Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

AI 简述这是一项III期试验，比较立体定向放疗与中等分割放疗用于生化复发或寡转移前列腺癌。

?

适用疾病: Stage IIB Prostate Cancer；Stage IIC Prostate Cancer；Stage III Prostate Cancer
干预: 未列出
地点: United States
申办方: Mayo Clinic in Arizona

正在招募 Phase 2, Phase 3

NCI NCT06367972 / NCI-2024-03278

Local Consolidative Therapy to Extend the Efficacy of Systemic Therapy in Oligoprogressive Metastatic Cancer, EXTEND-OP Trial

AI 简述这是一项II/III期试验，研究局部巩固治疗联合系统治疗用于寡进展转移性癌症，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 3

NCI NCT06650579 / NCI-2024-07761

Leuprolide and Abiraterone Acetate (AA) versus Relugolix and AA for the Treatment of Non-Metastatic Recurrent Prostate Cancer, the REVELUTION-2 Trial

AI 简述这是一项III期试验，在美国比较Leuprolide或Relugolix联合阿比特龙用于非转移性复发前列腺癌。

?

适用疾病: Stage I Prostate Cancer；Stage II Prostate Cancer；Stage III Prostate Cancer
干预: 未列出
地点: United States
申办方: Emory University Hospital/Winship Cancer Institute

正在招募 Phase 3

NCI NCT06931340 / NCI-2025-00838

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

AI 简述这是一项III期试验，在激素治疗和阿帕他胺基础上加用多西他赛用于转移性前列腺癌，在美国开展。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Castration-Sensitive Prostate Adenocarcinoma；Metastatic Prostatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 3

NCI NCT07200830 / NCI-2025-06146

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and its Effect on Patients with Advanced Prostate Cancer, RECIPROCAL Trial

AI 简述这是一项III期试验，研究不同给药方案的Lutetium 177Lu PSMA RLT用于晚期前列腺癌。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma；Metastatic Prostatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 3 药物其他手术/操作

ClinicalTrials.gov / NCI NCT03678025 / NCI-2018-01738

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

AI 简述这是一项III期试验，研究标准全身治疗联合或不联合局部治疗用于转移性前列腺癌。

?

适用疾病: Castration Levels of Testosterone；Metastatic Prostatic Adenocarcinoma；Stage IV Prostate Cancer AJCC v8
干预: Abiraterone，Bicalutamide，Degarelix，Docetaxel
地点: United States，Chile，Colombia，Mexico 等 1 个
申办方: SWOG Cancer Research Network

正在招募 Phase 3 药物

ClinicalTrials.gov NCT03903835

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

AI 简述这是一项III期试验，比较Enzalutamide、Abiraterone等用于转移性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)；Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
干预: Enzalutamide Oral Capsule，Abiraterone Oral Tablet，Carboplatin，Cabazitaxel 60 mg Solution for Injection
地点: Belgium，Norway，Sweden，Switzerland
申办方: Karolinska Institutet

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT04242017

Long-term Better Than Short-term ADT With Salvage RT

AI 简述这是一项II/III期试验，在比利时比较不同时长ADT联合挽救放疗用于前列腺癌。

?

适用疾病: Prostate Cancer
干预: Triptoreline
地点: Belgium
申办方: Universitaire Ziekenhuizen KU Leuven

正在招募 Phase 3 放疗

ClinicalTrials.gov NCT04642027

PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy

AI 简述这是一项III期试验，研究PSMA-PET引导的低分次挽救性前列腺床放疗用于前列腺癌复发，在荷兰开展。

?

适用疾病: Prostate Cancer；Cancer Recurrence
干预: Conventional sEBRT，Hypofractionated sEBRT
地点: Netherlands
申办方: University Medical Center Groningen

正在招募 Phase 2, Phase 3 药物其他手术/操作

ClinicalTrials.gov NCT04787744

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

AI 简述这是一项II/III期试验，在美国比较标准全身治疗±PET指导局部治疗用于寡转移前列腺癌。

?

适用疾病: Prostate Cancer；Oligometastasis；Oligorecurrence
干预: PET-directed Local Therapy using Surgery，PET-directed Local Therapy using Radiation，Salvage Local Therapy for locally recurrent disease，Goserelin, Histrelin, Leuprolide & Triptorelin
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 3 联合产品放疗

ClinicalTrials.gov NCT04794777

Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer

AI 简述这是一项III期试验，比较个体化PSMA PET/CT靶向治疗与标准挽救放疗用于复发性前列腺癌。

?

适用疾病: Prostate Cancer
干预: Individualised therapy，Standard salvage therapy
地点: Sweden
申办方: Stefan Carlsson

正在招募 Phase 3 药物

ClinicalTrials.gov NCT04916613

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

AI 简述这是一项III期试验，比较ADT联合或不联合Darolutamide用于体弱的新发转移性前列腺癌，在比利时、法国、德国、爱尔兰等国开展。

?

适用疾病: Prostate Cancer Metastatic
干预: Darolutamide 300 mg，Placebo，Androgen deprivation therapy
地点: Belgium，France，Germany，Ireland 等 8 个
申办方: UNICANCER

正在招募 Phase 3 药物其他

ClinicalTrials.gov NCT05352178

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

AI 简述这是一项III期试验，研究转移定向治疗用于寡复发前列腺癌。

?

适用疾病: Prostate Cancer；Prostate Cancer Recurrent；Prostate Cancer Metastatic
干预: Radiotherapy (SBRT) and/or surgery (metastasectomy)，Androgen deprivation therapy，Androgen receptor targeted therapy
地点: Belgium
申办方: Universitaire Ziekenhuizen KU Leuven

正在招募 Phase 3 药物其他放疗

ClinicalTrials.gov NCT05448547

Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer

AI 简述这是一项III期试验，比较放疗或手术与初始观察用于高风险前列腺癌，在丹麦、芬兰、挪威、瑞典开展。

?

适用疾病: Prostate Cancer
干预: Radiotherapy or surgery，initial observation，Hormone therapy
地点: Denmark，Finland，Norway，Sweden
申办方: Sven Löffeler

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05974774

Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

AI 简述这是一项III期试验，研究间歇性雄激素剥夺治疗用于前列腺癌，在丹麦、法国、西班牙等地开展。

?

适用疾病: Prostate Cancer
干预: iMAB，cMAB
地点: Denmark，France，Spain
申办方: European Organisation for Research and Treatment of Cancer - EORTC

正在招募 Phase 2, Phase 3 药物放疗

ClinicalTrials.gov NCT06282588

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

AI 简述这是一项II/III期试验，研究Darolutamide联合放疗用于高风险前列腺癌。

?

适用疾病: Prostate Cancer
干预: Darolutamide，Darolutamide matched placebo，Radiotherapy，Zoladex 3.6Mg Implant
地点: Belgium
申办方: Cancer Research Antwerp

正在招募 Phase 3 药物其他放疗

ClinicalTrials.gov NCT06320067

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

AI 简述这是一项III期试验，研究SABR、177Lu-PSMA-617等治疗转移性激素敏感性前列腺癌，在英国开展。

?

适用疾病: Prostate Cancer Metastatic
干预: Stereotactic Ablative Body Radiotherapy (SABR)，177Lu-PSMA-617，Androgen Deprivation Therapy (ADT)，Androgen Receptor Signalling Inhibitor (ARPI)
地点: United Kingdom
申办方: University College, London

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06439225

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

AI 简述这是一项在加拿大开展的III期试验，研究铂类和紫杉烷类化疗用于DNA损伤修复基因突变的转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Metastatic Prostate Cancer
干预: Docetaxel，Carboplatin
地点: Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 3 药物手术/操作

ClinicalTrials.gov / NCI NCT06470243 / NCI-2024-04336

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

AI 简述这是一项III期试验，在美国和墨西哥开展，比较Cabazitaxel联合Carboplatin与Cabazitaxel单药用于转移性去势抵抗性前列腺癌。

?

适用疾病: Castration-Resistant Prostate Carcinoma；Stage IVB Prostate Cancer AJCC v8；Stage IVB Prostate Cancer
干预: Biospecimen Collection，Bone Scan，Cabazitaxel，Carboplatin
地点: United States，Mexico
申办方: SWOG Cancer Research Network

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06496581

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

AI 简述这是一项3期试验，研究177Lu-PSMA-617联合标准治疗用于转移性前列腺癌，在法国开展。

?

适用疾病: Prostate Cancer Metastatic
干预: 177Lu-PMSA-617，Standard of Care
地点: France
申办方: UNICANCER

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06520345 / NCI-2024-07863

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

AI 简述这是一项III期试验，研究177Lu-TLX591联合标准治疗用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Adenocarcinoma
干预: 177Lu-TLX591，Enzalutamide，Abiraterone，Docetaxel
地点: United States，Australia，Canada，New Zealand 等 2 个
申办方: Telix Pharmaceuticals (Innovations) Pty Limited

正在招募 Phase 3 其他手术/操作

ClinicalTrials.gov / NCI NCT06563388 / NCI-2024-06801

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

AI 简述这是一项III期试验，研究立体定向消融放疗用于寡转移癌症患者，包括肺癌、结直肠癌和前列腺癌。

?

适用疾病: Oligometastasis；Lung Cancer；Colo-rectal Cancer
干预: Stereotactic Ablative Radiotherapy，Best Practice
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 3 手术/操作放疗

ClinicalTrials.gov NCT06585007

Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer

AI 简述这是一项III期试验，研究放疗/转移灶切除用于寡进展去势抵抗性前列腺癌。在比利时开展。

?

适用疾病: Castration-resistant Prostate Cancer；Oligoprogressive
干预: Radiotherapy，metastasectomy
地点: Belgium
申办方: Universitaire Ziekenhuizen KU Leuven

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06592924 / NCI-2024-07535

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

AI 简述这是一项III期试验，在美国、加拿大等地开展，研究多西他赛联合雄激素受体通路抑制剂用于转移性激素敏感性前列腺癌且PSA反应不佳的患者。

?

适用疾病: Prostate Cancer (Adenocarcinoma)；Stage IVB Prostate Cancer；Metastatic Castration-Sensitive Prostate Carcinoma
干预: Abiraterone，Enzalutamide，Apalutamide，Darolutamide (BAY 1841788)
地点: United States，Canada，Uruguay，Mexico
申办方: Canadian Cancer Trials Group

正在招募 Phase 3 药物放疗

ClinicalTrials.gov NCT06625970

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

AI 简述这是一项III期试验，研究Darolutamide联合立体定向放射治疗用于高风险局限性前列腺癌。

?

适用疾病: High Risk Prostate Carcinoma；Prostate Cancer
干预: Darolutamide，Stereotactic Body RadioTherapy (SBRT)，ADT (Standard of Care)，radiotherapy
地点: France，Martinique
申办方: UNICANCER

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07213674 / NCI-2025-07528

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

AI 简述这是一项III期试验，研究Xaluritamig联合Abiraterone用于未经化疗的转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Adenocarcinoma
干预: Xaluritamig，Abiraterone acetate，Docetaxel，Cabazitaxel
地点: United States，Australia，Austria，Belgium 等 14 个
申办方: Amgen

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07333066

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

AI 简述这是一项III期试验，研究多西他赛联合Apalutamide用于转移性激素敏感性前列腺癌。在法国、德国、意大利、葡萄牙等地开展。

?

适用疾病: Metastatic Hormone-sensitive Prostate Cancer
干预: Apalutamide (Erleada™) 60 mg or 240 mg tablets，Docetaxel
地点: France，Germany，Italy，Portugal 等 1 个
申办方: Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07365995

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

AI 简述这是一项III期试验，比较BNT324与多西他赛用于转移性去势抵抗性前列腺癌。在美国开展。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: BNT324，Docetaxel，Prednisone/prednisolone
地点: United States
申办方: BioNTech SE

正在招募 Phase 2, Phase 3 药物放疗

ClinicalTrials.gov NCT07426055

PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer

AI 简述这是一项II/III期试验，比较SBRT单药与全腺体加量放疗用于局限性前列腺癌，在波兰等地开展。

?

适用疾病: Prostate Cancer (Adenocarcinoma)；Prostate Brachytherapy；Stereotactic Body Radiation Therapy (SBRT)
干预: Stereotactic Body Radiotherapy (SBRT) Monotherapy，External Beam Radiotherapy (EBRT) Backbone，High-Dose-Rate Brachytherapy Boost，Low-Dose-Rate Brachytherapy Boost
地点: Poland
申办方: Affidea Nu-med Center of Oncological DIagnostics and Therapy

正在招募 Phase 2, Phase 3 药物放疗

ClinicalTrials.gov NCT07426094

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

AI 简述这是一项II/III期试验，比较前列腺单独与联合盆腔加量放疗用于淋巴结阳性前列腺癌，在波兰等地开展。

?

适用疾病: Prostate Cancer；Brachytherapy；Stereotactic Body Radiation Therapy (SBRT)
干预: Ultrahypofractionated Whole-Pelvis Radiotherapy，SBRT-Based Prostate Radiotherapy (No Boost)，Ablative Prostate Boost，Intermediate Nodal Dose Escalation
地点: Poland
申办方: Affidea Nu-med Center of Oncological DIagnostics and Therapy

正在招募 Phase 2

NCI NCT01296243 / NCI-2012-00357

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

AI 简述这是一项II期试验，研究Tesetaxel用于化疗初治的转移性去势抵抗性前列腺癌。

?

适用疾病: Hormone-Resistant Prostate Cancer；Stage IV Prostate Cancer
干预: 未列出
地点: United States
申办方: Genta Inc

正在招募 Phase 1, Phase 2

NCI NCT03190941 / NCI-2018-03522

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

AI 简述这是一项I/II期试验，研究输注靶向KRAS G12V的T细胞用于HLA-A*11:01阳性的胰腺癌、胃癌等患者。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT04143789 / NCI-2019-07561

Evaluation of AP-002 in Patients With Solid Tumors

AI 简述这是一项I/II期试验，评估AP-002用于晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Altum Pharmaceuticals Inc

正在招募 Phase 1, Phase 2

NCI NCT04145375 / NCI-2019-07571

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

AI 简述这是一项I/II期延续试验，为ZEN003694临床获益者继续用药，用于前列腺癌，在美国开展。

?

适用疾病: Castration-Resistant Prostate Cancer；Stage IV Prostate Cancer；Stage IVA Prostate Cancer
干预: 未列出
地点: United States
申办方: Zenith Epigenetics

正在招募 Phase 1, Phase 2

NCI NCT04145622 / NCI-2020-03139

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

AI 简述这是一项I/II期试验，研究Ifinatamab Deruxtecan用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 2

NCI NCT04449549 / NCI-2020-04956

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

AI 简述这是一项II期试验，研究尼罗替尼和紫杉醇用于罕见肿瘤，在美国开展。

?

适用疾病: Lepidic Adenocarcinoma；Malignant Solid Tumor；Stage IV Anal Cancer
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 2

NCI NCT04947254 / NCI-2021-05724

Androgen Ablation Therapy with or without Niraparib after Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

AI 简述这是一项2期试验，研究放疗后雄激素剥夺治疗联合或不联合Niraparib用于高危局限性或局部晚期前列腺癌。

?

适用疾病: Stage IIC Prostate Cancer；Stage III Prostate Cancer；Stage IIIA Prostate Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04723810 / NCI-2022-03872

Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care

AI 简述这是一项I/II期试验，研究吲哚青绿用于实体瘤术中成像，在美国开展。

?

适用疾病: Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Sarcoma
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05358379 / NCI-2022-04029

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

AI 简述这是一项I/II期试验，研究CYC140用于晚期实体瘤和淋巴瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Peripheral T-Cell Lymphoma, Unclassifiable
干预: 未列出
地点: United States
申办方: Cyclacel Pharmaceuticals, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05417594 / NCI-2022-05317

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

AI 简述这是一项1/2期试验，研究AZD9574单药或联合其他抗癌药用于晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 2

NCI NCT05454488 / NCI-2022-05462

Focal Cryotherapy for the Treatment of Intermediate Risk Prostate Cancer

AI 简述这是一项II期试验，研究局灶冷冻疗法用于中风险前列腺癌。

?

适用疾病: Stage I Prostate Cancer；Stage II Prostate Cancer；Stage IIIA Prostate Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05394103 / NCI-2022-10300

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究CDK7抑制剂Q901用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Qurient Co., Ltd.

正在招募 Phase 1, Phase 2

NCI NCT05592626 / NCI-2023-00103

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究STAR0602用于多种晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: Marengo Therapeutics, Inc.

正在招募 Phase 2

NCI NCT05751941 / NCI-2023-02058

Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer with PSA Progression while on NHA and LHRH Analog

AI 简述这是一项II期试验，研究Sipuleucel-T联合或不联合新型激素药用于转移性去势抵抗性前列腺癌。

?

适用疾病: Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer；Biochemically Recurrent Prostate Carcinoma
干预: 未列出
地点: United States
申办方: Moffitt Cancer Center

正在招募 Phase 2

NCI NCT05806515 / NCI-2023-02356

Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

AI 简述这是一项II期试验，研究卡铂术前化疗用于BRCA突变高危前列腺癌。

?

适用疾病: Stage IIIB Prostate Cancer；Stage IIIC Prostate Cancer；Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: SWOG

正在招募 Phase 1, Phase 2

NCI NCT05458544 / NCI-2023-03186

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application

AI 简述这是一项I/II期试验，研究[Lu-177]Ludotadipep用于去势抵抗性前列腺癌。

?

适用疾病: Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Prostate Cancer
干预: 未列出
地点: United States
申办方: FutureChem

正在招募 Phase 1, Phase 2

NCI NCT04969315 / NCI-2023-03874

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

AI 简述这是一项I/II期试验，研究TT-10和TT-4单药或联合用于多种晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Portage Biotech

正在招募 Phase 2

NCI NCT05969860 / NCI-2023-05420

At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls

AI 简述这是一项II期试验，比较在家与在医院进行癌症治疗用于晚期癌症患者。

?

适用疾病: Advanced Malignant Solid Tumor；Advanced Head and Neck Cancer；Advanced Melanoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 2

NCI NCT05832086 / NCI-2023-05452

Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

AI 简述这是一项II期试验，研究间歇性禁食改善前列腺癌控制和代谢结果。

?

适用疾病: Stage IV Prostate Cancer；Castration-Sensitive Prostate Carcinoma；Metastatic Prostatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: Cedars-Sinai Medical Center

正在招募 Phase 2

NCI NCT06039371 / NCI-2023-05597

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

AI 简述这是一项II期试验，研究超生理雄激素增强治疗用于转移性去势抵抗性前列腺癌。

?

适用疾病: Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Prostatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 1, Phase 2

NCI NCT05934539 / NCI-2023-05619

ALG.APV-527 First-in-human Study

AI 简述这是一项I/II期试验，研究ALG.APV-527用于转移性尿路上皮癌及晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Aptevo Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT05684965 / NCI-2023-06173

XTX301 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究XTX301用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Xilio Development, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05754580 / NCI-2023-06520

High-Dose Rate Brachytherapy Boost with Stereotactic Radiation Body Therapy to the Prostate and Pelvic Lymph Nodes for the Treatment of Unfavorable Intermediate or Higher Risk Prostate Cancer

AI 简述这是一项I/II期试验，在美国研究高剂量率近距离放疗联合立体定向放疗用于前列腺癌。

?

适用疾病: Stage I Prostate Cancer；Stage II Prostate Cancer；Stage III Prostate Cancer
干预: 未列出
地点: United States
申办方: University of Nebraska Medical Center

正在招募 Phase 2

NCI NCT05502315 / NCI-2023-06543

Cabozantinib and Nivolumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, CANOPY Trial

AI 简述这是一项II期试验，研究Cabozantinib联合Nivolumab用于转移性去势抵抗性前列腺癌。

?

适用疾病: Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer；Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: UC San Diego Moores Cancer Center

正在招募 Phase 2

NCI NCT06067269 / NCI-2023-06647

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients with Prostate Cancer, HEATWAVE Trial

AI 简述这是一项II期试验，研究阿帕鲁胺联合立体定向体部放疗用于前列腺癌。在美国开展。

?

适用疾病: Stage II Prostate Cancer；Stage IIIA Prostate Cancer；Stage IIIB Prostate Cancer
干预: 未列出
地点: United States
申办方: UCLA / Jonsson Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05785741 / NCI-2023-06649

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究DB-1310用于晚期/转移性实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 2

NCI NCT06216249 / NCI-2023-07172

Randomized Phase 2 Trial of Flexible and Extended Dosing of 177Lu-PSMA-617 Molecular Radioligand Therapy for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

AI 简述这是一项II期试验，研究177Lu-PSMA-617用于转移性去势抵抗性前列腺癌。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: 未列出
地点: United States
申办方: UCLA / Jonsson Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT05915442 / NCI-2023-07333

Evaluation of Zimberelimab, Etrumadenant, Quemliclustat and Stereotactic Body Radiation Therapy for the Treatment of Hormone Sensitive Oligometastatic Prostate Cancer

AI 简述这是一项II期试验，在美国开展，研究Zimberelimab、Etrumadenant、Quemliclustat联合立体定向放疗用于激素敏感寡转移前列腺癌。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Prostatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06085729 / NCI-2023-08684

Pegargiminase (ADI-PEG 20), Carboplatin, and Cabazitaxel for the Treatment of Aggressive Variant Metastatic Prostate Cancer

AI 简述这是一项早期试验，研究Pegargiminase、卡铂、卡巴他赛用于侵袭性变异转移性前列腺癌。

?

适用疾病: Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Small Cell Neuroendocrine Prostate Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05000294 / NCI-2023-08761

Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types

AI 简述这是一项I/II期试验，研究阿特珠单抗联合Tivozanib用于免疫冷肿瘤类型，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；FIGO Stage IVA Ovarian Cancer；FIGO Stage IVB Ovarian Cancer
干预: 未列出
地点: United States
申办方: UF Health Cancer Institute - Gainesville

正在招募 Phase 2

NCI NCT06129851 / NCI-2023-09079

Relugolix in Combination with Radiation Therapy for Treating Patients with High Risk Prostate Cancer

AI 简述这是一项2期试验，研究Relugolix联合放疗用于高风险前列腺癌。

?

适用疾病: Stage IIC Prostate Cancer；Stage III Prostate Cancer；Stage IV Prostate Cancer
干预: 未列出
地点: United States
申办方: University of Kansas Cancer Center

正在招募 Phase 2

NCI NCT06101290 / NCI-2023-09084

Locally Ablative Therapy for the Treatment of Oligo-progressive Prostate Cancer, Urinary Tract Cancer or Kidney Cancer, LAYOVER Trial

AI 简述这是一项II期试验，在美国研究局部消融疗法用于寡进展性前列腺癌、泌尿系癌或肾癌。

?

适用疾病: Metastatic Urothelial Cancer；Stage IV Prostate Cancer；Stage IV Renal Cell Cancer
干预: 未列出
地点: United States
申办方: University of California Davis Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT06096870 / NCI-2023-09282

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

AI 简述这是一项II期试验，在美国研究Enzalutamide和PDS01ADC用于PET阳性复发性前列腺癌。

?

适用疾病: Recurrent Prostate Cancer
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 2

NCI NCT06200103 / NCI-2023-10664

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

AI 简述这是一项II期试验，研究降低177Lu-PSMA-617给药频率用于转移性去势抵抗性前列腺癌。

?

适用疾病: Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 2

NCI NCT06288113 / NCI-2024-00310

Re-treatment with 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

AI 简述这是一项II期试验，在已接受过177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者中再次使用该药物。

?

适用疾病: Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer
干预: 未列出
地点: United States
申办方: UCLA / Jonsson Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05914116 / NCI-2024-01206

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

AI 简述这是一项I/IIa期试验，在美国研究DB-1311/BNT324用于晚期/转移性实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 2

NCI NCT06111781 / NCI-2024-01759

SBRT and Relugolix for the Treatment of Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer, SUGAR Trial

AI 简述这是一项II期试验，研究SBRT联合Relugolix用于中危前列腺癌。

?

适用疾病: Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: Yale University

正在招募 Phase 2

NCI NCT06378866 / NCI-2024-02978

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

AI 简述这是一项II期试验，研究立体定向放疗联合或不联合雄激素受体通路抑制剂用于生化复发前列腺癌。

?

适用疾病: Biochemically Recurrent Prostate Carcinoma；Recurrent Castration-Sensitive Prostate Carcinoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 1, Phase 2

NCI NCT06253130 / NCI-2024-03012

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究IMP1734用于晚期实体瘤。在美国开展。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Eikon Therapeutics

正在招募 Phase 2

NCI NCT06369610 / NCI-2024-03020

Risk Stratified De-escalated Hormone Therapy with Radiation Therapy for the Treatment of Prostate Cancer

AI 简述这是一项II期试验，研究风险分层降级激素治疗联合放疗用于前列腺癌。

?

适用疾病: Oligometastatic Prostate Carcinoma；Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Arizona

正在招募 Phase 2

NCI NCT05726292 / NCI-2024-03178

Enzalutamide Plus Relacorilant with Androgen Deprivation Therapy for the Treatment of Patients with High-Risk Localized Prostate Cancer before Surgery

AI 简述这是一项II期试验，研究Enzalutamide联合Relacorilant及雄激素剥夺疗法用于高危局限性前列腺癌。

?

适用疾病: Stage IIC Prostate Cancer；Stage III Prostate Cancer；Stage IVA Prostate Cancer
干预: 未列出
地点: United States
申办方: University of Chicago Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT06384222 / NCI-2024-03418

An Investigational Scan (HP 13C MRI) for Assessing Response to Treatment with Abiraterone Acetate and Prednisone prior to Surgery in Patients with High-Risk Prostate Cancer

AI 简述这是一项II期试验，研究HP 13C MRI评估阿比特龙和泼尼松治疗对高风险前列腺癌的应答，在美国开展。

?

适用疾病: Stage IIC Prostate Cancer；Stage III Prostate Cancer；Stage IVA Prostate Cancer
干预: 未列出
地点: United States
申办方: University of California San Francisco

正在招募 Phase 1, Phase 2

NCI NCT06399757 / NCI-2024-04491

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究APL-5125用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Apollo Therapeutics Ltd

正在招募 Phase 2

NCI NCT06526299 / NCI-2024-05664

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

AI 简述这是一项II期试验，在美国开展，研究177Lu-PSMA-617强化治疗用于低PSMA表达转移性去势抵抗性前列腺癌。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 2

NCI NCT06212583 / NCI-2024-06274

Standard of Care Treatment (Hormonal Therapy and Stereotactic Ablative Radiation Therapy) Alone or in Combination with Niraparib, Abiraterone and Prednisone for the Treatment of Metastatic Prostate Cancer, KNIGHTS Trial

AI 简述这是一项2期试验，研究标准治疗（激素治疗和立体定向放疗）联合Niraparib、Abiraterone和Prednisone用于转移性前列腺癌。

?

适用疾病: Metastatic Malignant Neoplasm to Soft Tissues；Stage IVB Prostate Cancer；Metastatic Malignant Neoplasm to the Bone
干预: 未列出
地点: United States
申办方: University of Maryland/Greenebaum Cancer Center

正在招募 Phase 2

NCI NCT06567314 / NCI-2024-07130

Ivonescimab for the Treatment of Patients with Locally Advanced, Unresectable and/or Metastatic Cutaneous Squamous Cell Cancer and Metastatic Castration-resistant Prostate Cancer

AI 简述这是一项II期试验，研究Ivonescimab用于局部晚期不可切除和/或转移性皮肤鳞状细胞癌及转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Skin Squamous Cell Carcinoma；Locally Advanced Skin Squamous Cell Carcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06111313 / NCI-2024-08321

MRI-Guided LEAD Stereotactic Radiotherapy with or without Ultra-Short Term Androgen Suppression Therapy for the Treatment of Prostate Cancer, the Miami UAdapt Trial

AI 简述这是一项II期试验，MRI引导的立体定向放疗联合或不联合短期雄激素抑制治疗用于前列腺癌。

?

适用疾病: Stage I Prostate Cancer；Stage II Prostate Cancer；Stage III Prostate Cancer
干预: 未列出
地点: United States
申办方: University of Miami Miller School of Medicine-Sylvester Cancer Center

正在招募 Phase 2

NCI NCT06591819 / NCI-2024-09077

High Dose Rate Brachytherapy Boost with Ultrahypofractionated Whole Pelvis Proton Radiation Therapy for the Treatment of High or Unfavorable Intermediate Risk Prostate Cancer

AI 简述这是一项II期试验，在开展高剂量率近距离治疗联合超分级全骨盆质子放疗用于高危或不利中危前列腺癌。

?

适用疾病: Stage IIB Prostate Cancer；Stage IIC Prostate Cancer；Stage IIIB Prostate Cancer
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 2

NCI NCT06014255 / NCI-2024-09884

Enoblituzumab before Radical Prostatectomy versus Radical Prostatectomy Alone for the Treatment of High-Risk Localized Prostate Cancer

AI 简述这是一项II期试验，研究Enoblituzumab用于根治性前列腺切除术前治疗高危局限性前列腺癌。

?

适用疾病: Stage I Prostate Cancer；Stage II Prostate Cancer；Stage III Prostate Cancer
干预: 未列出
地点: United States
申办方: Johns Hopkins University/Sidney Kimmel Cancer Center

正在招募 Phase 2

NCI NCT06817668 / NCI-2025-00596

Elective Pelvic Ultra Hypofractionated Irradiation Treatment with High Dose Rate Brachytherapy Boost for the Treatment of Unfavorable and Higher Risk Prostate Cancer

AI 简述这是一项II期试验，研究盆腔超低分次放疗联合高剂量率近距离放疗推量用于高危前列腺癌，在美国开展。

?

适用疾病: Prostate Cancer
干预: 未列出
地点: United States
申办方: Indiana University/Melvin and Bren Simon Cancer Center

正在招募 Phase 2

NCI NCT06402357 / NCI-2025-01924

High Intensity Focused Ultrasound for the Treatment of Radiorecurrent Localized Prostate Cancer

AI 简述这是一项II期试验，研究高强度聚焦超声用于治疗放疗后局部复发的前列腺癌。

?

适用疾病: Stage I Prostate Cancer；Stage II Prostate Cancer；Stage IIIA Prostate Cancer
干预: 未列出
地点: United States
申办方: UF Health Cancer Institute - Gainesville

正在招募 Phase 2

NCI NCT05790213 / NCI-2025-04277

Focal Therapy Combined with Androgen Deprivation Therapy for the Treatment of Localized Intermediate Risk Prostate Cancer

AI 简述这是一项II期试验，研究局部治疗联合雄激素剥夺疗法用于中危局限性前列腺癌。

?

适用疾病: Stage IIB Prostate Cancer；Stage IIC Prostate Cancer；Localized Prostate Carcinoma
干预: 未列出
地点: United States
申办方: University of Chicago Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06943521 / NCI-2025-04636

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究MT-4561用于多种晚期实体瘤，在美国和日本开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Tanabe Pharma America, Inc.

正在招募 Phase 2

NCI NCT07073794 / NCI-2025-04662

Evaluating In Home Cancer Therapy versus In Clinic Cancer Therapy in Black Men with Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer

AI 简述这是一项II期试验，比较居家与院内癌症治疗用于黑人男性前列腺癌患者，在美国开展。

?

适用疾病: Stage III Prostate Cancer；Stage IV Prostate Cancer；Locally Advanced Prostate Carcinoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 2

NCI NCT06798558 / NCI-2025-04728

Lu-177-PSMA-617 before Radical Prostatectomy for the Treatment of High Risk Localized Prostate Cancer

AI 简述这是一项II期试验，研究Lu-177-PSMA-617用于高危局限性前列腺癌。

?

适用疾病: Stage IIC Prostate Cancer；Stage IIIA Prostate Cancer；Localized Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: Hackensack University Medical Center

正在招募 Phase 2

NCI NCT06953089 / NCI-2025-05085

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

AI 简述这是一项II期试验，研究DB-1311联合BNT327或DB-1305用于晚期转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 2

NCI NCT07150715 / NCI-2025-05583

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide with Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

AI 简述这是一项II期试验，在美国研究α或β放射性核素联合立体定向放疗用于复发性寡转移前列腺腺癌。

?

适用疾病: Recurrent Prostate Adenocarcinoma；Oligometastatic Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: UCLA / Jonsson Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT07142967 / NCI-2025-05646

MR-Linac-Guided Stereotactic Body Radiation Therapy with Androgen Deprivation Therapy for the Treatment of Locally Recurrent Prostate Adenocarcinoma

AI 简述这是一项II期试验，在美国研究磁共振引导放射治疗用于局部复发前列腺腺癌。

?

适用疾病: Recurrent Prostate Adenocarcinoma；Localized Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: Laura and Isaac Perlmutter Cancer Center at NYU Langone

正在招募 Phase 1, Phase 2

NCI NCT06907043 / NCI-2025-06439

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

AI 简述这是一项I/II期试验，研究PARP1抑制剂EIK1004用于晚期实体瘤。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Eikon Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT06725758 / NCI-2025-08359

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

AI 简述这是一项I/II期试验，在美国开展，研究ODM-212用于晚期实体瘤。

?

适用疾病: Metastatic Head and Neck Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Orion Corporation, Orion Pharma

正在招募 Phase 1, Phase 2

NCI NCT07145255 / NCI-2026-00044

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

AI 简述这是一项I/II期试验，在美国研究ADC用于多种晚期难治实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: mBrace Therapeutics

正在招募 Phase 2

NCI NCT07325721 / NCI-2026-01786

Hypofractionated Radiotherapy with a Focal Microboost for the Treatment of High-Risk and Locally Advanced Prostate Cancer

AI 简述这是一项II期试验，研究大分割放疗联合局部微加重用于高风险和局部晚期前列腺癌，在美国开展。

?

适用疾病: Stage IIB Prostate Cancer；Stage IIC Prostate Cancer；Stage III Prostate Cancer
干预: 未列出
地点: United States
申办方: Medical University of South Carolina

正在招募 Phase 2

NCI NCT07027124 / NCI-2026-03666

Neoadjuvant Leuprolide Acetate and Darolutamide with Pembrolizumab, Followed by Adjuvant Pembrolizumab for the Treatment of Intermediate or High-Risk Localized and Locally Advanced Prostate Adenocarcinoma

AI 简述这是一项II期试验，研究新辅助亮丙瑞林和Darolutamide联合帕博利珠单抗，随后辅助帕博利珠单抗用于中高风险局限性和局部晚期前列腺腺癌，在美国开展。

?

适用疾病: Stage I Prostate Cancer；Stage II Prostate Cancer；Stage III Prostate Cancer
干预: 未列出
地点: United States
申办方: Icahn School of Medicine at Mount Sinai

正在招募 Phase 1, Phase 2

NCI NCT07446855 / NCI-2026-03698

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

AI 简述这是一项1/2期试验，研究AZD4956单药或联合用药用于晚期/转移性HRD实体瘤，在美国等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 2

NCI NCT07364071 / NCI-2026-03910

External Beam Radiation Therapy plus Short-Term Androgen Deprivation Therapy and Optional Androgen Receptor Pathway Inhibitor for the Treatment of Localized Prostate Cancer, SENTRY Trial

AI 简述这是一项II期试验，研究外照射放疗联合短期雄激素剥夺治疗及可选雄激素受体通路抑制剂用于局限性前列腺癌，在美国开展。

?

适用疾病: Stage IIIB Prostate Cancer；Stage IIIC Prostate Cancer；Stage IVA Prostate Cancer
干预: 未列出
地点: United States
申办方: UC San Diego Moores Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03522064

Bipolar Androgen Therapy + Carboplatin in mCRPC

AI 简述这是一项II期试验，研究双极雄激素疗法联合卡铂用于去势抵抗性前列腺癌。在澳大利亚开展。

?

适用疾病: Castration-resistant Prostate Cancer；Homologous Recombination Deficiency
干预: Testosterone Enanthate 100 MG/ML Injectable Solution，Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
地点: Australia
申办方: St Vincent's Hospital, Sydney

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT03833921 / NCI-2021-01135

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

AI 简述这是一项II期试验，研究阿比特龙/泼尼松在不同种族/族裔转移性激素初治前列腺癌中的反应。

?

适用疾病: Prostate Cancer Metastatic；Prostate Cancer；Stage IV Prostate Cancer
干预: Abiraterone Acetate，Prednisone
地点: United States
申办方: Martha Mims

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT03866382 / NCI-2019-01266

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

AI 简述这是一项II期试验，研究Nivolumab、Ipilimumab联合Cabozantinib用于罕见泌尿生殖系统肿瘤。

?

适用疾病: Bladder Adenocarcinoma；Bladder Clear Cell Adenocarcinoma；Bladder Mixed Adenocarcinoma
干预: Biospecimen Collection，Bone Scan，Cabozantinib S-malate，Computed Tomography
地点: United States，Puerto Rico
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03972657 / NCI-2019-05728

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

AI 简述这是一项I/II期试验，研究REGN5678单用或联合Cemiplimab用于转移性去势抵抗性前列腺癌等。在美国开展。

?

适用疾病: Metastatic Castration-Resistant Prostate Cancer (mCRPC)；Clear Cell Renal Cell Carcinoma (ccRCC)；Castration-Resistant Prostate Cancer
干预: REGN5678，Cemiplimab
地点: United States
申办方: Regeneron Pharmaceuticals

正在招募 Phase 1, Phase 2 药物手术/操作放疗

ClinicalTrials.gov NCT04086290

National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients

AI 简述这是一项I/II期试验，研究手术+SBRT用于转移性前列腺癌，在丹麦开展。

?

适用疾病: Prostate Cancer Metastatic
干预: RARP，SBRT，ADT
地点: Denmark
申办方: Peter Busch Østergren

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04104776 / NCI-2020-01007

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

AI 简述这是一项I/II期试验，研究Tulmimetostat用于晚期实体瘤和淋巴瘤。

?

适用疾病: Advanced Solid Tumor；Diffuse Large B Cell Lymphoma；Lymphoma, T-Cell
干预: Tulmimetostat，Enzalutamide
地点: United States，France，Italy，Poland 等 3 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT04175431 / NCI-2019-07437

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

AI 简述这是一项II期试验，在美国研究PSMA或FACBC PET/CT指导的治疗用于前列腺腺癌。

?

适用疾病: Prostate Adenocarcinoma
干预: Positron Emission Tomography，Lymphadenectomy，Radiation Therapy，Abiraterone Acetate
地点: United States
申办方: University of Washington

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04363164 / NCI-2021-06077

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

AI 简述这是一项II期试验，研究睾酮和恩杂鲁胺用于转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Castration Resistant Metastatic Prostate Cancer；Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer
干预: Testosterone cypionate，Enzalutamide，Testosterone enanthate
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT04402151 / NCI-2021-08952

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

AI 简述这是一项II期试验，研究PSMA PET/MR引导的立体定向体部放疗用于高危前列腺癌，在美国开展。

?

适用疾病: Prostate Cancer；Stage IIC Prostate Cancer；Stage III Prostate Cancer
干预: PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC，Stereotactic Body Radiation Therapy (SBRT)
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04503265 / NCI-2020-14258

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AI 简述这是一项I/II期试验，研究AMXI-5001用于晚期实体瘤。在美国开展。

?

适用疾病: Advanced Malignant Neoplasm；Breast Cancer；Ovarian Cancer
干预: AMXI-5001:Dose Escalation Phase I，AMXI-5001:Dose Expansion Phase II
地点: United States
申办方: AtlasMedx, Incorporated

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04550494 / NCI-2020-06906

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

AI 简述这是一项II期试验，研究Talazoparib用于携带DNA修复变异的晚期癌症患者。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8；Castration-Resistant Prostate Carcinoma
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04585750

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

AI 简述这是一项I/II期试验，研究rezatapopt用于TP53 Y220C突变晚期实体瘤，在美澳法德开展。

?

适用疾病: Advanced Solid Tumor；Advanced Malignant Neoplasm；Metastatic Cancer
干预: rezatapopt，pembrolizumab
地点: United States，Australia，France，Germany 等 5 个
申办方: PMV Pharmaceuticals, Inc

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04633252 / NCI-2020-11631

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

AI 简述这是一项I/II期试验，研究PDS01ADC联合多西他赛和阿比特龙用于转移性前列腺癌，在美国开展。

?

适用疾病: Cancer Of Prostate；Prostate Neoplasms；Castration-Resistant Prostate Cancer
干预: PDS01ADC，Docetaxel，M7824，Prednisone
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT04704505

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

AI 简述这是一项II期试验，研究双极雄激素治疗联合镭-223用于转移性去势抵抗性前列腺癌，在美国和巴西开展。

?

适用疾病: Prostate Adenocarcinoma；Metastatic Prostate Adenocarcinoma；Castration-resistant
干预: radium-223，Bipolar Androgen Therapy (BAT)
地点: United States，Brazil
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04868604 / NCI-2022-04853

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

AI 简述这是一项I/II期试验，研究64Cu-SAR-bisPSMA和67Cu-SAR-bisPSMA用于转移性去势抵抗性前列腺癌。

?

适用疾病: Prostatic Neoplasms, Castration-Resistant；Castration-Resistant Prostate Cancer；Stage IV Prostate Cancer
干预: 64Cu-SAR-bisPSMA，67Cu-SAR-bisPSMA
地点: United States
申办方: Clarity Pharmaceuticals Ltd

正在招募 Phase 1, Phase 2 诊断检测药物

ClinicalTrials.gov / NCI NCT04946370 / NCI-2025-02625

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

AI 简述这是一项I/II期试验，研究Pembrolizumab联合雄激素受体抑制剂加或不加225Ac-J591用于转移性去势抵抗性前列腺癌。

?

适用疾病: Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: 225Ac-J591，Pembrolizumab，Androgen receptor inhibitor，68Ga-PSMA-11
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05011383 / NCI-2021-12544

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

AI 简述这是一项II期试验，研究高剂量睾酮用于ATM/CDK12/CHEK2突变转移性前列腺癌。

?

适用疾病: Metastatic Prostate Cancer；Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer
干预: High dose testosterone
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05113537 / NCI-2021-11123

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

AI 简述这是一项I/II期试验，研究Abemaciclib联合177Lu-PSMA-617用于转移性去势抵抗前列腺癌。

?

适用疾病: Castration-Resistant Prostate Carcinoma；Metastatic Prostate Adenocarcinoma；Stage IV Prostate Cancer AJCC v8
干预: Abemaciclib，Lutetium Lu 177-PSMA-617
地点: United States
申办方: Vadim S Koshkin

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05125016 / NCI-2021-13606

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

AI 简述这是一项I/II期试验，研究REGN4336单用或联合REGN5678用于晚期前列腺癌，在美国开展。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Castration-Resistant Prostate Cancer；Prostate Cancer
干预: REGN4336，REGN5678
地点: United States
申办方: Regeneron Pharmaceuticals

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05155046 / NCI-2021-13965

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

AI 简述这是一项II期试验，研究18F-DCFPyL成像评估立体定向放疗反应用于局限性前列腺癌。

?

适用疾病: Localized Prostate Cancer；Localized Prostate Carcinoma
干预: 18F-DCFPyL
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05168618 / NCI-2021-13110

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项II期试验，研究Cabozantinib联合Atezolizumab用于转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Castration-Resistant Prostate Carcinoma；Metastatic Prostate Adenocarcinoma；Stage IV Prostate Cancer AJCC v8
干预: Atezolizumab，Cabozantinib S-malate
地点: United States
申办方: University of Utah

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT05223803 / NCI-2022-10566

TERPS Trial for de Novo Oligometastic Prostate Cancer

AI 简述这是一项II期试验，在美国研究前列腺放疗联合全身治疗和SABR用于新发寡转移前列腺癌。

?

适用疾病: Prostate Cancer；Oligometastatic Disease；Stage IVB Prostate Cancer
干预: Prostate radiation (XRT)，Systemic Therapy，Stereotactic ablative radiation therapy (SABR)
地点: United States
申办方: University of Maryland, Baltimore

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05348876

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

AI 简述这是一项IV期试验，在印度研究Darolutamide联合标准雄激素剥夺疗法用于高危非转移性去势抵抗性前列腺癌。

?

适用疾病: Non-metastatic Castration-resistant Prostate Cancer
干预: Darolutamide (Nubeqa, BAY1841788)
地点: India
申办方: Bayer

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT05404139

Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

AI 简述这是一项II期试验，研究雄激素受体通路抑制剂联合ADT及转移灶定向治疗用于寡转移前列腺癌，在加拿大开展。

?

适用疾病: Metastatic Prostate Cancer
干预: Enzalutamide，Standard of Care SBRT and ADT
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1, Phase 2 诊断检测药物

ClinicalTrials.gov / NCI NCT05413850 / NCI-2023-00300

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

AI 简述这是一项1/2期试验，研究177Lu rhPSMA-10.1用于转移性去势抵抗性前列腺癌，在美国、比利时等地开展。

?

适用疾病: Prostate Cancer；Metastatic Castration-resistant Prostate Cancer；mCRPC
干预: Lutetium (177Lu) rhPSMA-10.1 Injection，18F-rhPSMA-7.3 injection (in phase 1 only)
地点: United States，Belgium，Germany，Netherlands 等 1 个
申办方: Blue Earth Therapeutics Ltd

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05422911

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

AI 简述这是一项2期试验，比较阿比特龙、恩杂鲁胺或阿帕鲁胺用于去势敏感性前列腺癌。

?

适用疾病: Metastatic Cancer；Neoplasm, Prostate；Castrate-sensitive
干预: Abiraterone acetate，Apalutamide，Enzalutamide
地点: United States
申办方: Sun Pharmaceutical Industries Limited

正在招募 Phase 2 其他放疗

ClinicalTrials.gov NCT05457699

Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)

AI 简述这是一项II期试验，研究消融放疗用于转移性前列腺癌。

?

适用疾病: Prostate Cancer Metastatic
干预: Metastasis directed radiotherapy (MDRT)，no MDRT
地点: Canada
申办方: Centre hospitalier de l'Université de Montréal (CHUM)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05521412

EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T

AI 简述这是一项I/II期试验，研究[161Tb]Tb-PSMA-I&T用于转移性去势抵抗性前列腺癌，在澳大利亚开展。

?

适用疾病: Prostate Cancer；Metastatic Castration-resistant Prostate Cancer
干预: [ 161 Tb]Tb PSMA I&T
地点: Australia
申办方: Peter MacCallum Cancer Centre, Australia

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05534646 / NCI-2024-09561

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

AI 简述这是一项II期试验，研究Apalutamide联合Carotuximab用于转移性去势抵抗性前列腺癌。

?

适用疾病: Castration-resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: Apalutamide，Carotuximab
地点: United States
申办方: Edwin Posadas, MD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05560659

Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy

AI 简述这是一项II期试验，研究Lu-PSMA用于寡转移前列腺癌立体定向消融放疗后。

?

适用疾病: Oligometastatic Prostate Cancer
干预: 177Lu-PSMA
地点: Australia，Israel
申办方: Peter MacCallum Cancer Centre, Australia

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05563558

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

AI 简述这是一项II期试验，研究帕博利珠单抗、卡铂联合卡巴他赛用于转移性去势抵抗性前列腺癌。

?

适用疾病: Prostate Cancer Metastatic
干预: Pembrolizumab，Carboplatin，Cabazitaxel
地点: Spain
申办方: Fundacion Oncosur

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT05616650 / NCI-2022-09907

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

AI 简述这是一项II期试验，研究立体定向体部放疗用于单灶前列腺癌。

?

适用疾病: Prostatic Neoplasms；Prostate Cancer；Prostate Adenocarcinoma
干预: 18F-DCFPyL，Stereotactic Body Radiation Therapy
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT05656794

Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer

AI 简述这是一项II期试验，巩固性前列腺放疗用于转移性前列腺癌。

?

适用疾病: Prostate Metastases
干预: Radiotherapy
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT05691465 / NCI-2022-05173

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

AI 简述这是一项II期试验，研究Lutetium Lu 177 Dotatate用于转移性前列腺癌伴神经内分泌分化，在美国开展。

?

适用疾病: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation；Metastatic Prostate Neuroendocrine Carcinoma；Metastatic Prostate Small Cell Neuroendocrine Carcinoma
干预: Biospecimen Collection，Computed Tomography，Gallium Ga 68-DOTATATE，Lutetium Lu 177 Dotatate
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05720130

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

AI 简述这是一项I/II期试验，在澳大利亚研究[²¹²Pb]Pb-ADVC001用于转移性前列腺癌。

?

适用疾病: Prostate Cancer；Metastatic Castration-resistant Prostate Cancer；Metastatic Hormone Sensitive Prostate Cancer
干预: [²¹²Pb]Pb-ADVC001 (Phase 1b)，[²¹²Pb]Pb-ADVC001 (Phase 2a)
地点: Australia
申办方: AdvanCell Pty Limited

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05762536

Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC

AI 简述这是一项II期试验，研究Darolutamide联合多西他赛或卡巴他赛用于转移性去势抵抗性前列腺癌。在荷兰开展。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Darolutamide，Docetaxel or cabazitaxel
地点: Netherlands
申办方: Erasmus Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05766371 / NCI-2023-01660

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

AI 简述这是一项II期试验，研究Pembrolizumab联合177Lu-PSMA-617用于去势抵抗性前列腺癌。在美国开展。

?

适用疾病: Castrate Resistant Prostate Cancer；Metastatic Castration-resistant Prostate Cancer；Prostate Cancer
干预: Pembrolizumab，177Lu-PSMA-617
地点: United States
申办方: University of California, San Francisco

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05873192 / NCI-2023-03938

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

AI 简述这是一项II期试验，研究Talazoparib联合Enzalutamide用于前列腺癌，在美国开展。

?

适用疾病: Prostate Cancer；Stage IVA Prostate Cancer；Prostate Adenocarcinoma
干预: ADT，Enzalutamide，Talazoparib，Degarelix
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT05893381

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

AI 简述这是一项II期试验，比较Lu-PSMA联合立体定向放疗与单纯放疗用于前列腺癌。

?

适用疾病: Prostate Cancer
干预: [177Lu]Lu-PSMA I&T，Stereotactic Radiotherapy
地点: Italy
申办方: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05919264

FOG-001 in Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，在美国和澳大利亚开展，研究FOG-001联合化疗或免疫治疗用于局部晚期或转移性实体瘤。

?

适用疾病: Cancer；Colorectal Cancer；Solid Tumor
干预: FOG-001，mFOLFOX-6，Nivolumab，Trifluridine/tipiracil
地点: United States，Australia
申办方: Parabilis Medicines, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06059118 / NCI-2024-09882

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项2期试验，研究DFMO、睾酮和恩杂鲁胺用于转移性去势抵抗性前列腺癌。

?

适用疾病: Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: DFMO，testosterone cypionate，Luteinizing hormone-releasing hormone (LHRH) analogue，Enzalutamide
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06084338

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

AI 简述这是一项II期试验，在无去势条件下采用立体定向消融放疗、Pluvicto、局部睾酮治疗转移性前列腺癌。

?

适用疾病: Prostate Cancer
干预: stereotactic ablative radiotherapy，Pluvicto，topical testosterone
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06085664 / NCI-2023-08688

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

AI 简述这是一项早期试验，研究REGN5678用于高危局限性前列腺癌术前治疗。

?

适用疾病: Prostate Cancer；Radical Prostatectomy；Stage IIC Prostate Cancer
干预: REGN5678，Piflufolastat F18
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06100705 / NCI-2024-00050

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

AI 简述这是一项II期试验，在美国研究Sipuleucel-T联合双极雄激素疗法用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: Testosterone Cypionate，Sipuleucel-T
地点: United States
申办方: Yale University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06126731

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

AI 简述这是一项1/2期试验，研究抗生素联合恩杂鲁胺用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
干预: Enzalutamide 40mg，Amoxicillin 500mg，Metronidazole 400mg，Vancomycin 125mg
地点: Switzerland，United Kingdom
申办方: Institute of Cancer Research, United Kingdom

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06134232 / NCI-2024-07759

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

AI 简述这是一项II期试验，研究Sipuleucel-T用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-Resistant Prostate Cancer (mCRPC)；Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer
干预: Sipuleucel-T Injection
地点: United States
申办方: Dendreon

正在招募 Phase 2 药物其他手术/操作

ClinicalTrials.gov / NCI NCT06145633 / NCI-2023-08921

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项II期试验，研究Vorinostat和177Lu-PSMA-617用于PSMA低表达的转移性去势抵抗性前列腺癌。

?

适用疾病: Castration-Resistant Prostate Carcinoma；Metastatic Prostate Adenocarcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Bone Scan，Computed Tomography
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 药物其他放疗

ClinicalTrials.gov / NCI NCT06150417 / NCI-2024-01892

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

AI 简述这是一项II期试验，研究转移导向放疗联合长期雄激素剥夺治疗用于前列腺癌。

?

适用疾病: Prostate Cancer；Malignant Neoplasm of Prostate；Secondary Malignant Neoplasm of Prostate
干预: Androgen deprivation therapy (ADT)，Androgen receptor signaling inhibitor (ARSI)，Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)，Metastasis directed radiotherapy (MDRT)
地点: United States
申办方: Case Comprehensive Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06190899 / NCI-2024-00175

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项I/II期试验，研究Gedatolisib联合Darolutamide用于转移性去势抵抗性前列腺癌。

?

适用疾病: mCRPC (Metastatic Castration-resistant Prostate Cancer)；Genital Diseases, Male；Urogenital Diseases, Male
干预: Gedatolisib，Darolutamide
地点: United States，France，Spain，United Kingdom
申办方: Celcuity Inc

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06220188

PSMA-RLT in Biochemically Recurrent PCa

AI 简述这是一项II期试验，研究[177Lu]Lu-PSMA I&T用于生化复发的前列腺癌，在奥地利开展。

?

适用疾病: Prostate Cancer Recurrent
干预: [177Lu]Lu-PSMA I&T
地点: Austria
申办方: Medical University of Vienna

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06228053 / NCI-2024-02347

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

AI 简述这是一项II期试验，研究SX-682联合恩杂鲁胺用于转移性去势抵抗性前列腺癌。在美国开展。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: SX-682，Enzalutamide
地点: United States
申办方: Syntrix Biosystems, Inc.

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06236139 / NCI-2023-10316

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项1/2期试验，研究STEAP1 CAR-T细胞联合恩杂鲁胺用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-Resistant Prostate Carcinoma；Metastatic Prostate Adenocarcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Anti-STEAP1 CAR T-cells，Biopsy Procedure，Biospecimen Collection，Bone Scan
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT06244004 / NCI-2023-10764

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

AI 简述这是一项II期试验，研究FDG-PET引导的转移灶定向放疗用于转移性激素敏感性前列腺癌。

?

适用疾病: Castration-Sensitive Prostate Carcinoma；Metastatic Prostate Carcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Antiandrogen Therapy，Bone Scan，Computed Tomography，Cytotoxic Chemotherapy
地点: United States
申办方: Northwestern University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06259123

Neoadjuvant PSMA-RLT in Oligometastatic PCa

AI 简述这是一项II期试验，在奥地利研究PSMA-RLT用于寡转移前列腺癌的术前治疗。

?

适用疾病: Prostate Cancer
干预: [177Lu]Lu-PSMA I&T
地点: Austria
申办方: Medical University of Vienna

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06267729 / NCI-2024-01754

Study of AZD0754 in Participants With Metastatic Prostate Cancer

AI 简述这是一项I/II期试验，研究AZD0754用于转移性前列腺癌，在美国、澳大利亚、西班牙等地开展。

?

适用疾病: Metastatic Prostate Cancer；Castration-Resistant Prostate Cancer；Stage IV Prostate Cancer
干预: AZD0754，AZD2287
地点: United States，Australia，Spain
申办方: AstraZeneca

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06347705 / NCI-2024-03050

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

AI 简述这是一项II期试验，研究2141-V11联合标准治疗用于前列腺癌。

?

适用疾病: Prostate Cancer
干预: 2141-V11 Antibody
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06353386 / NCI-2024-06341

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

AI 简述这是一项I/II期试验，研究Opevesostat单药或联合Olaparib等用于转移性去势抵抗性前列腺癌，在美国、澳大利亚等地开展。

?

适用疾病: Prostatic Neoplasms, Castration-Resistant；Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer
干预: Opevesostat，Olaparib，Docetaxel，Cabazitaxel
地点: United States，Australia，Canada，Chile 等 16 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT06392295 / NCI-2024-04698

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

AI 简述这是一项II期试验，在寡转移前列腺癌患者中研究PSMA引导的主动脉旁放疗，在美国等地开展。

?

适用疾病: Prostate Cancer；Prostate Adenocarcinoma；Hormone Sensitive Prostate Cancer
干预: Para Aortic Radiation Therapy: Photon Therapy，Para Aortic Radiation Therapy: Proton Therapy，Androgen Deprivation Therapy，Androgen Receptor Signaling Inhibitor
地点: United States
申办方: University of Miami

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06395519

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

AI 简述这是一项I/II期试验，研究PARG抑制剂ETX-19477用于晚期实体恶性肿瘤。在美国开展。

?

适用疾病: Advanced or Metastatic Solid Tumors；Breast Cancer；Ovarian Cancer
干预: ETX-19477
地点: United States
申办方: 858 Therapeutics, Inc.

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT06401980

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

AI 简述这是一项II期试验，研究Darolutamide用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Darolutamide，Standard of care
地点: Switzerland
申办方: Swiss Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06449781

177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer

AI 简述这是一项II期试验，研究177Lu-PSMA用于高/极高风险前列腺癌的术后辅助治疗，在波兰开展。

?

适用疾病: Prostate Cancer
干预: Lutetium (177Lu) vipivotide tetraxetan
地点: Poland
申办方: Maria Sklodowska-Curie National Research Institute of Oncology

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06457919 / NCI-2024-05117

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

AI 简述这是一项I/II期试验，在美国研究Tinengotinib联合标准治疗用于前列腺癌。

?

适用疾病: Prostate Cancer；Castration-Resistant Prostate Cancer；Metastatic Prostate Cancer
干预: Tinengotinib，abiraterone acetate with prednisone，Enzalutamide
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06480110

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

AI 简述这是一项I/II期试验，研究Ebastine联合多西他赛用于去势抵抗性转移性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Docetaxel + Ebastine，Docetaxel
地点: Denmark
申办方: Rigshospitalet, Denmark

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06533644 / NCI-2025-03072

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

AI 简述一项II期试验，研究SV-102用于转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Stage III Prostate Cancer；Stage IVB Prostate Cancer
干预: Partial Oncolysis，SV-102
地点: United States
申办方: Syncromune, Inc.

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06549465 / NCI-2024-07295

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

AI 简述这是一项II期试验，研究Ac-225 Rosopatamab Tetraxetan用于PSMA PET阳性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: PSMA PET-Positive Castration-Resistant Prostate Cancer；Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer
干预: In-111 rosopatamab tetraxetan，45 kBq/kg Ac-225 rosopatamab tetraxetan，55 kBq/kg Ac-225 rosopatamab tetraxetan，60 kBq/kg Ac-225 rosopatamab tetraxetan
地点: United States
申办方: Convergent Therapeutics

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06568562 / NCI-2024-09848

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项II期试验，研究XL092用于转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Adenocarcinoma
干预: XL092
地点: United States
申办方: University of Utah

正在招募 Phase 1, Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT06574880 / NCI-2025-00036

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

AI 简述这是一项I/II期试验，研究立体定向体部放疗联合177Lu-PSMA用于局部晚期前列腺癌。

?

适用疾病: Malignant Neoplasm of Prostate；Locally Advanced Prostate Cancer；Stage IIIB Prostate Cancer
干预: Lu-PSMA-617，5-fraction Stereotactic Body Radiation Therapy (SBRT)
地点: United States
申办方: Angela Y. Jia, MD PhD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06582628

Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)

AI 简述这是一项II期试验，研究他拉唑帕尼联合恩杂鲁胺用于阿比特龙进展后的转移性前列腺癌。在西班牙开展。

?

适用疾病: Metastatic Prostate Cancer
干预: Enzalutamide capsule，Enzalutamide capsule and Talazoparib capsule
地点: Spain
申办方: Fundacion Oncosur

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06594926

Working Out M0 Bipolar Androgen Therapy

AI 简述这是一项II期试验，研究丙酸睾酮用于前列腺癌，在澳大利亚开展。

?

适用疾病: Prostate Cancer
干预: Testosterone Enanthate
地点: Australia
申办方: Australian and New Zealand Urogenital and Prostate Cancer Trials Group

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06610825

Castrate Resistant Prostate Cancer Enhertu Therapy

AI 简述这是一项II期试验，研究Enhertu用于去势抵抗性前列腺癌。

?

适用疾病: Prostate Cancer Metastatic；Prostate Cancer；CRPC
干预: Enhertu
地点: United States
申办方: Washington D.C. Veterans Affairs Medical Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06615752

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

AI 简述这是一项I/II期试验，研究绿茶槲皮素联合多西他赛用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)
干预: green tea and quercetin + docetaxel，Placebo + docetaxel
地点: United States
申办方: Charles Drew University of Medicine and Science

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06616155 / NCI-2024-06533

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项I/II期试验，研究Ruxolitinib联合Enzalutamide用于转移性去势抵抗性前列腺癌。

?

适用疾病: Castration-Resistant Prostate Carcinoma；Metastatic Prostate Adenocarcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Biopsy，Biospecimen Collection，Bone Scan，Computed Tomography
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06616597 / NCI-2025-07268

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

AI 简述这是一项II期试验，评估甲硝唑联合阿比特龙用于转移性前列腺癌。

?

适用疾病: Prostate Cancer (Adenocarcinoma)；Metastatic Prostate Cancer；Stage IVB Prostate Cancer
干预: Abiraterone acetate，Dexamethasone，Metronidazole
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2 药物其他手术/操作

ClinicalTrials.gov / NCI NCT06632977 / NCI-2024-04960

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

AI 简述这是一项II期试验，研究靶向治疗用于转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Castration-Resistant Prostate Carcinoma；Stage IVB Prostate Cancer AJCC v8；Stage IVB Prostate Cancer
干预: Genetic testing，Valemetostat Tosylate，Magnetic Resonance Imaging，Computed Tomography
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06654336

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

AI 简述这是一项II期试验，研究复发导向治疗联合或不联合雄激素剥夺治疗用于放射复发寡转移激素敏感性前列腺癌，在加拿大开展。

?

适用疾病: Prostate Adenocarcinoma；Castration Sensitive Prostate Cancer
干预: Recurrence-directed therapy (RDT)，ELIGARD 22.5mg
地点: Canada
申办方: Ontario Clinical Oncology Group (OCOG)

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06738303 / NCI-2025-04726

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

AI 简述这是一项II期试验，比较Cabazitaxel联合或不联合卡铂与177Lu-PSMA-617用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Prostate Cancer；Metastatic Castration-resistant Prostate Cancer；Stage IVB Prostate Cancer
干预: Cabazitaxel and carboplatin，Lu-PSMA-617
地点: United States
申办方: Case Comprehensive Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06758882

Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET

AI 简述这是一项II期试验，研究手术联合Apalutamide用于高危前列腺癌。

?

适用疾病: High Risk Prostate Cancer
干预: Apalutamide，Androgen receptor (AR) inhibitor
地点: Italy
申办方: Marco Oderda

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06782555 / NCI-2025-00867

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

AI 简述这是一项I/II期试验，研究Evofosfamide联合Zalifrelimab和Balstilimab用于转移性前列腺癌、头颈鳞癌及胰腺癌。

?

适用疾病: Metastatic Prostate Cancer；Metastatic Head and Neck Squamous Cell Carcinoma；Metastatic Pancreatic Cancer
干预: Evofosfamide，Zalifrelimab，Balstilimab
地点: United States
申办方: ImmunoGenesis

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06785636 / NCI-2025-02182

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

AI 简述这是一项I/II期试验，研究Pocenbrodib单用或联合Darolutamide用于转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: mCRPC (Metastatic Castration-resistant Prostate Cancer)；Prostate Cancer；Stage IVB Prostate Cancer
干预: Pocenbrodib，Pocenbrodib and Darolutamide
地点: United States
申办方: Pathos AI, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06800313 / NCI-2025-07447

Study of HLD-0915 in Patients With Metastatic Prostate Cancer

AI 简述这是一项I/II期试验，研究HLD-0915用于转移性前列腺癌。

?

适用疾病: Metastatic Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Adenocarcinoma
干预: HLD-0915 Hard Capsule，HLD-0915 Tablet，HLD-0915 Soft Capsule
地点: United States，United Kingdom
申办方: Halda Therapeutics OpCo, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06842498 / NCI-2025-01692

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

AI 简述这是一项II期试验，研究FG-3246用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Adenocarcinoma
干预: FG-3246
地点: United States
申办方: Kyntra Bio

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06844383 / NCI-2026-00266

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

AI 简述这是一项II期试验，研究Talazoparib联合或不联合Enzalutamide用于既往接受阿比特龙的前列腺癌。

?

适用疾病: Prostate Cancer (Adenocarcinoma)；mCRPC (Metastatic Castration-resistant Prostate Cancer)；Stage IVB Prostate Cancer
干预: Talazoparib with enzalutamide，Talazoparib
地点: United States
申办方: Prostate Cancer Clinical Trials Consortium

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06849544

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

AI 简述这是一项II期试验，研究OTL78四种剂量方案用于前列腺癌手术。

?

适用疾病: Prostate Cancer Surgery；Prostate Cancer Metastatic Disease
干预: 0.03mg/kg ZOPOCIANINE given day of surgery，0.06mg/kg ZOPOCIANINE given day of surgery，0.03mg/kg ZOPOCIANINE given day prior to surgery，0.06mg/kg ZOPOCIANINE given days prior to surgery
地点: United States
申办方: Clinton Bahler

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06863272 / NCI-2025-03341

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

AI 简述这是一项I/II期试验，研究Ifinatamab Deruxtecan单药或联合用于转移性去势抵抗性前列腺癌。

?

适用疾病: Castration-Resistant Prostatic Cancer；Metastasis；Stage IVB Prostate Cancer
干预: Docetaxel，Ifinatamab Deruxtecan，MK-5684，Abiraterone
地点: United States，Argentina，Australia，Brazil 等 15 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06866938

Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer

AI 简述这是一项II期试验，研究177Lu-PSMA再次治疗用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: [177Lu]Lu-PSMA-617 (Pluvicto, Novartis)
地点: France
申办方: Hospices Civils de Lyon

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06922318 / NCI-2025-06185

The COSMYC Trial (COmbined Suppression of MYC)

AI 简述这是一项II期试验，研究ZEN-3694联合恩杂鲁胺等用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: ZEN-3694，Testosterone cypionate，Enzalutamide，Luteinizing hormone-releasing hormone (LHRH) analogue
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2 其他放疗

ClinicalTrials.gov NCT06927635

Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

AI 简述这是一项II期试验，研究立体定向体部放疗对比标准治疗用于前列腺少进展性癌症，在加拿大开展。

?

适用疾病: Castrate Resistance Prostate Cancer；OligoProgressive Metastatic Disease
干预: Stereotactic Body Radiation Therapy (SBRT)，Systemic therapy
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06957691

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

AI 简述这是一项II期试验，在美国研究Fezolinetant治疗前列腺癌雄激素剥夺引起的血管舒缩症状。

?

适用疾病: Prostate Cancer；Prostate Cancer (Adenocarcinoma)；Prostate Cancer Metastatic Disease
干预: fezolinetant - reference formulation，Placebo
地点: United States
申办方: Shehzad Basaria, M.D.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06972628

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

AI 简述这是一项II期试验，在美国开展，研究177Lu-PSMA-617用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-Resistant Prostate Cancer；Prostate Cancer Patients With Bone Metastasis；Prostate Cancer (CRPC)
干预: Administering Lutetium-177-PSMA-617 (PLUVICTO)
地点: United States
申办方: Ebrahim S Delpassand

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06990880 / NCI-2026-01628

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

AI 简述这是一项一/二期试验，研究GSK5458514单药或联合其他抗癌药用于前列腺癌。在美国、加拿大、法国、日本等地开展。

?

适用疾病: Neoplasms, Prostate；Stage IV Prostate Cancer；Metastatic Castration-Resistant Prostate Adenocarcinoma
干预: GSK5458514
地点: United States，Canada，France，Japan 等 1 个
申办方: GlaxoSmithKline

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07002320

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

AI 简述这是一项I/II期试验，研究SX-682联合阿帕鲁胺用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
干预: SX-682，Apalutamide
地点: Switzerland，United Kingdom
申办方: Institute of Cancer Research, United Kingdom

正在招募 Phase 2 药物其他手术/操作

ClinicalTrials.gov / NCI NCT07025369 / NCI-2025-03965

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

AI 简述这是一项II期试验，研究Relugolix用于改善高风险或极高风险前列腺癌患者的PSMA PET/CT成像，在美国开展。

?

适用疾病: Prostate Adenocarcinoma；Stage IIC Prostate Cancer AJCC v8；Stage III Prostate Cancer AJCC v8
干预: Biospecimen Collection，Computed Tomography，Flotufolastat F-18 Gallium，Laparoscopic Radical Prostatectomy with Robotics
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT07038304

The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)

AI 简述这是一项II期试验，研究转移定向放疗用于寡进展去势抵抗性前列腺癌，在荷兰开展。

?

适用疾病: Prostate Cancer (Adenocarcinoma)；OligoProgressive Metastatic Disease；Castration Resistant Metastatic Prostate Cancer
干预: Metastasis directed radiotherapy
地点: Netherlands
申办方: University Medical Center Groningen

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07111507 / NCI-2025-05914

A Study of Tarlatamab for People With Prostate Cancer

AI 简述这是一项II期试验，在美国开展，研究Tarlatamab用于转移性前列腺癌。

?

适用疾病: Metastatic Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Small Cell Neuroendocrine Prostate Cancer
干预: Tarlatamab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07142551 / NCI-2026-02258

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

AI 简述这是一项II期试验，在美国研究睾酮联合Darolutamide用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Prostatic Adenocarcinoma
干预: Testosterone cypionate，Luteinizing hormone-releasing hormone (LHRH) analogue，Darolutamide
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07189871 / NCI-2026-03797

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究177Lu-BetaBart用于复发/难治性局部晚期不可切除或转移性实体瘤。

?

适用疾病: Castration-Resistant Prostate Cancer (CRPC)；Colorectal Cancer；NSCLC (Non-small Cell Lung Cancer)
干预: 177Lu-BetaBart
地点: United States
申办方: Radiopharm Theranostics, Ltd

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07208240

Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial.

AI 简述这是一项I/II期试验，研究Tb-PSMA-I&T用于高风险前列腺癌。在以色列开展。

?

适用疾病: High Risk Prostate Cancer
干预: Tb-PSMA-I&T (Tb-PSMA)
地点: Israel
申办方: Rabin Medical Center

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT07210086

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

AI 简述这是一项II期试验，评估前列腺癌寡转移治疗后PSMA-PET反应。在美国开展。

?

适用疾病: Prostate Cancer
干预: ADT，ARSI，No ADT/ARSI -decline
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07216248 / NCI-2025-07798

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

AI 简述这是一项2期试验，研究PSA触发下的个体化管理用于转移性激素敏感性前列腺癌。

?

适用疾病: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)；Stage IVB Prostate Cancer；Metastatic Castration-Sensitive Prostate Adenocarcinoma
干预: relugolix + ARPI，Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI，relugolix or androgen deprivation therapy (ADT) + ARPI，relugolix + ARPI.
地点: United States
申办方: University of Utah

正在招募 Phase 1, Phase 2 药物放疗

ClinicalTrials.gov NCT07226986

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

AI 简述这是一项I/II期试验，研究AMO959联合177Lu-vipivotide tetraxetan及ARPI用于PSMA阳性mCRPC，在美国、澳大利亚、法国、德国等地开展。

?

适用疾病: PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
干预: AMO959，AAA617，Enzalutamide，Abiraterone
地点: United States，Australia，France，Germany 等 3 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 2 放疗

ClinicalTrials.gov / NCI NCT07234981 / NCI-2026-01099

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer

AI 简述这是一项II期试验，在美国研究PSMA-PET引导的挽救性放疗剂量降低用于前列腺癌复发。

?

适用疾病: Prostate Cancer；Biochemically Recurrent Prostate Carcinoma；Recurrent Prostate Cancer
干预: PSMA-guided Salvage Radiation
地点: United States
申办方: University of Nebraska

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT07237269 / NCI-2026-01098

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

AI 简述这是一项II期试验，研究Abi/Pred+ADT对比ADT用于PSMA阳性前列腺癌。

?

适用疾病: Prostate Cancer；Stage I Prostate Cancer；Stage II Prostate Cancer
干预: Androgen Deprivation Therapy (ADT)，Abiraterone，Prednisone，Radiation Therapy
地点: United States
申办方: University of Nebraska

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07255664

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

AI 简述这是一项I/IIa期试验，在德国研究TIL免疫疗法用于转移性结直肠癌和前列腺癌。

?

适用疾病: Metastatic Colorectal Cancer；Prostate Cancer Metastatic；Prostate Cancer Locally Advanced
干预: CC-38，Pembrolizumab，Cyclophosphamid，Interleukin-2
地点: Germany
申办方: CuraCell TX AB

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT07285694 / NCI-2026-00799

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

AI 简述这是一项I/II期试验，研究AB-3028用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration Resistant Prostate Cancer (mCRPC)；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Adenocarcinoma
干预: AB-3028
地点: United States
申办方: Arsenal Biosciences, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07287150 / NCI-2026-01298

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项II期试验，研究Inavolisib用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: Inavolisib，Enzalutamide，Abiraterone，Docetaxel
地点: United States，Australia，Brazil，Canada 等 7 个
申办方: Hoffmann-La Roche

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07288359

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究GVV858单用或联合内分泌治疗用于HR+/HER2-乳腺癌和晚期实体瘤。

?

适用疾病: Advanced HR+/HER2- Breast Cancer；Advanced CCNE1-amplified Solid Tumors；Metastatic Castration-resistant Prostate Cancer
干预: GVV858，Fulvestrant，Letrozole
地点: United States，Czechia，Denmark，France 等 6 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07292168

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

AI 简述这是一项I/II期试验，在俄罗斯研究FGFR1抗体OM-RCA-01用于表达FGFR1的转移性肿瘤。

?

适用疾病: Renal Cell Carcinoma Metastatic；Prostate Cancer Metastatic；Non-small Cell Lung Cancer Metastatic
干预: humanized monoclonal anti-FGFR1 antibody OM-RCA-01
地点: Russia
申办方: Kidney Cancer Research Bureau

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07332455 / NCI-2026-04008

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

AI 简述这是一项I/II期试验，研究GSK5471713用于转移性去势抵抗性前列腺癌。

?

适用疾病: Neoplasms, Prostate；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Adenocarcinoma
干预: GSK5471713
地点: United States，Canada，Japan，South Korea
申办方: GlaxoSmithKline

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07341737

SL-28 for Advanced Solid Tumours

AI 简述这是一项1/2期试验，研究SL-28用于多种晚期实体瘤（如头颈癌、胰腺癌、肺癌）。在澳大利亚开展。

?

适用疾病: Head & Neck Cancer；Pancreas Carcinoma；Pancreas Cancer, Metastatic
干预: SL-28，SL-28，SL-28
地点: Australia
申办方: Second Life Therapeutics

正在招募 Phase 2 诊断检测药物放疗

ClinicalTrials.gov / NCI NCT07393867 / NCI-2026-02253

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

AI 简述这是一项II期试验，在美国开展，研究PSMA PET/CT引导下前列腺癌放疗联合内分泌治疗。

?

适用疾病: Intermediate Risk Prostate Cancer；High Risk Prostate Cancer；Prostate Cancer
干预: PSMA PET/CT，Androgen Deprivation Therapy (ADT) +/- bicalutamide，Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
地点: United States
申办方: Martin T. King, MD, PhD

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07414940

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

AI 简述这是一项I/II期试验，研究Actinium (225Ac) rhPSMA-10.1用于转移性去势抵抗性前列腺癌，在英国开展。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Metastatic Prostate Cancer；Prostate Cancer
干预: Actinium (225Ac) rhPSMA-10.1
地点: United Kingdom
申办方: University College, London

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07441889 / NCI-2026-04796

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

AI 简述这是一项I/II期试验，研究HER2 FPBMC用于转移性乳腺癌和前列腺癌。

?

适用疾病: Breast Cancer；Prostate Cancer；Stage IV Breast Cancer
干预: HER2 FPBMC
地点: United States
申办方: University of Virginia

正在招募 Phase 2 诊断检测药物手术/操作

ClinicalTrials.gov NCT07455903

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

AI 简述这是一项II期试验，研究新辅助雄激素剥夺治疗用于高危局限性前列腺癌，利用PSMA PET/CT评估。

?

适用疾病: Prostate Cancer；Localized Prostate Carcinoma
干预: Leuprolide，Degarelix，Relugolix，Triptorelin
地点: United States
申办方: Baptist Health South Florida

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07476001 / NCI-2026-02418

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

AI 简述这是一项II期试验，研究高剂量睾酮后行放射配体治疗用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: Testosterone cypionate (Tc)，ADT with Luteinizing hormone-releasing hormone (LHRH) analog，PSMA-617
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07529717

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

AI 简述这是一项I/II期试验，研究AZD8359用于转移性前列腺癌。

?

适用疾病: Metastatic Prostate Cancer
干预: AZD8359，AZD8359，AZD8359，AZD8359
地点: United States，Australia，South Korea
申办方: AstraZeneca

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07567846

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

AI 简述这是一项I/II期试验，研究GDC-1261用于晚期或转移性前列腺癌。

?

适用疾病: Advanced Prostate Cancer；Metastatic Prostate Cancer
干预: GDC-1261
地点: United States，Australia
申办方: Genentech, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07590934

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

AI 简述这是一项I/II期试验，研究多种抗癌药物用于转移性前列腺癌。

?

适用疾病: Metastatic Prostate Cancer
干预: AZD2265 (FPI-2265)，AZD9574，Docetaxel，AZD2287 (Imaging agent)
地点: United States，Australia，Germany，Italy 等 3 个
申办方: AstraZeneca

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07591467

Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer

AI 简述这是一项III期试验，在法国开展，研究卡铂强化治疗用于BRCA突变或神经内分泌分化侵袭性转移性去势敏感性前列腺癌。

?

适用疾病: BRCA-Mutated；Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer；Prostate Cancer
干预: Experimental
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07598032

Comparative Analysis of Immunological Responses to Vitamin D Replacement Therapy in Black and West African Men Diagnosed With Prostate Cancer: Elucidating Differential Effects on Immune Function Between Patients With Localized Disease and Those With Metastatic Progression

AI 简述这是一项III期试验，研究维生素D治疗对非裔前列腺癌患者免疫功能的影响，在尼日利亚开展。

?

适用疾病: Prostate Cancer (Adenocarcinoma)；Vitamin D on Tumor Response and Inflammatory Markers
干预: vitamin D 25(OH)D
地点: Nigeria
申办方: University of Ilorin Teaching Hospital

即将招募 Phase 4 药物

ClinicalTrials.gov NCT06660862

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

AI 简述这是一项4期试验，研究Darolutamide联合雄激素剥夺治疗用于转移性激素敏感性前列腺癌，在美国开展。

?

适用疾病: Prostate Cancer
干预: Darolutamide，Physician choice Androgen Deprivation (Hormone) Therapy
地点: United States
申办方: University of Chicago

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07226713

Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors

AI 简述这是一项II期试验，研究Pacritinib用于既往接受ARPI治疗后进展的转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Prostate Cancer
干预: Pacritinib
地点: United States
申办方: Medical College of Wisconsin

即将招募 Phase 2 放疗

ClinicalTrials.gov NCT07291557

PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer

AI 简述这是一项II期试验，在加拿大比较PSMA-PET指导的前列腺放疗与全盆腔放疗用于高危前列腺癌。

?

适用疾病: Prostate Cancer
干预: Prostate Only Radiation Therapy (PORT)，Prostate + Whole Pelvis Radiation Therapy (P-WPRT)
地点: Canada
申办方: AHS Cancer Control Alberta

即将招募 Phase 2 放疗

ClinicalTrials.gov NCT07354594

External Beam and Radioligand Radiotherapy for mCRPC

AI 简述这是一项II期试验，研究外照射放疗联合177Lu-PSMA放射性配体治疗用于转移性去势抵抗性前列腺癌，在加拿大开展。

?

适用疾病: Prostate Cancer Metastatic Castration-Resistant
干预: External Beam Radiotherapy Delivered Between Cycles of Radioligand Radiotherapy，Standard of care 177Lutetium-PSMA
地点: Canada
申办方: Centre hospitalier de l'Université de Montréal (CHUM)

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07441837

Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients

AI 简述这是一项II期试验，研究Terbium 161-PSMA用于前列腺癌。在土耳其开展。

?

适用疾病: Prostate Cancer
干预: Terbium 161- PSMA I&T
地点: Turkey (Türkiye)
申办方: Ankara University

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07550517

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

AI 简述这是一项2期试验，比较PSMA-617联合放疗与标准放疗用于高危局部前列腺癌。

?

适用疾病: High-Risk Localized Prostate Cancer
干预: EBRT + 6 mo ADT + 177Lu-PSMA-617，EBRT + 24 mo ADT
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07608718

Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

AI 简述这是一项II期试验，研究Zanzalitinib用于转移性去势抵抗性前列腺癌。在美国开展。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: Zanzalintinib
地点: United States
申办方: Pedro Barata, MD, MSc

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07645326

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

AI 简述这是一项II期试验，研究风险适应方案用于转移性激素敏感性前列腺癌，在美国开展。

?

适用疾病: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
干预: Androgen Deprivation Therapy (ADT)，Androgen Receptor Pathway Inhibitor (ARPI)，Prostate Radiation，Docetaxel
地点: United States
申办方: Georgetown University

即将招募 Phase 2 药物其他手术/操作

ClinicalTrials.gov / NCI NCT07650240 / NCI-2026-04100

Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

AI 简述这是一项2期试验，研究PSMA靶向治疗联合雄激素受体抑制用于低瘤负荷转移性前列腺癌。在美国开展。

?

适用疾病: Recurrent Prostate Adenocarcinoma；Stage IVB Prostate Cancer AJCC v8；Castration-Sensitive Prostate Cancer
干预: Abiraterone Acetate，Biospecimen Collection，Leuprolide Acetate，Lutetium Lu 177 Vipivotide Tetraxetan
地点: United States
申办方: Mayo Clinic

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07667400

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

AI 简述这是一项I/II期试验，研究SX-682联合多西他赛用于复发转移性头颈鳞癌等。

?

适用疾病: Head and Neck Cancer；Head and Neck Squamous Cell Carcinoma；Paranasal Sinus Neoplasms
干预: SX-682，DTX
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1

NCI NCT03098160 / NCI-2017-00995

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

AI 简述这是一项I期试验，研究Evofosfamide联合Ipilimumab用于多种晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Head and Neck Squamous Cell Carcinoma
干预: 未列出
地点: United States
申办方: Threshold Pharmaceuticals

正在招募 Phase 1

NCI NCT04693468 / NCI-2020-06041

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

AI 简述这是一项I期试验，研究Talazoparib联合Palbociclib、Axitinib或Crizotinib用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT04827810 / NCI-2022-01170

Gamitrinib for the Treatment of Advanced or Refractory Solid Tumors or Lymphoma

AI 简述这是一项I期试验，研究Gamitrinib用于晚期实体瘤或淋巴瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Fox Chase Cancer Center

正在招募 Phase 1

NCI NCT05242744 / NCI-2022-02381

PARP-1 Expression with 18F-FluorThanatrace PET/CT in Patients with Metastatic Prostate Cancer

AI 简述这是一项I期试验，使用18F-FluorThanatrace PET/CT评估转移性前列腺癌PARP-1表达。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Prostate Cancer
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募阶段未标明

NCI NCT05438563 / NCI-2022-03567

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

AI 简述这是一项NA期试验，在United States开展，研究MRI引导经尿道超声消融用于低至中危前列腺癌。

?

适用疾病: Stage I Prostate Cancer；Stage II Prostate Cancer；Prostate Cancer
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 1

NCI NCT05010200 / NCI-2022-04136

A Vaccine (PGV001) in Combination with Immunotherapy (CDX-301 and Poly-ICLC) for the Treatment of Prostate Cancer

AI 简述这是一项I期试验，研究疫苗PGV001联合免疫疗法用于前列腺癌。

?

适用疾病: Recurrent Prostate Adenocarcinoma；Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: Icahn School of Medicine at Mount Sinai

正在招募 Phase 1

NCI NCT05488548 / NCI-2022-10041

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

AI 简述这是一项I期试验，研究BET和CBP/p300双抑制剂用于晚期实体瘤和血液肿瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Epigenetix, Inc.

正在招募 Phase 1

NCI NCT05719558 / NCI-2023-03815

A Study of ASP1002 in Adults for Treatment of Solid Tumors

AI 简述这是一项I期试验，在美国研究ASP1002用于多种晚期实体瘤。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Astellas Pharma BV

正在招募 Phase 1

NCI NCT06014502 / NCI-2023-06808

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

AI 简述这是一项I期试验，研究IMGS-001用于复发或难治性晚期实体瘤，包括头颈癌、鼻咽癌等。

?

适用疾病: Metastatic Head and Neck Cancer；Malignant Solid Tumor；Stage III Nasopharyngeal Throat Cancer
干预: 未列出
地点: United States
申办方: ImmunoGenesis

正在招募 Phase 1

NCI NCT06136884 / NCI-2023-10499

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

AI 简述这是一项I期试验，研究口服TACC3抑制剂AO-252用于晚期实体瘤（伴或不伴脑转移）。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: A2A Pharmaceuticals Inc.

正在招募 Phase 1

NCI NCT05932862 / NCI-2023-10500

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究XL309单药或联合治疗用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage II Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Exelixis Inc

正在招募 Phase 1

NCI NCT05806814 / NCI-2024-01070

An Extended Course of Sipuleucel-T Immunotherapy for Treating Patients with Metastatic Castration-resistant Prostate Cancer, EXCITE Trial

AI 简述这是一项I期试验，研究延长Sipuleucel-T疗程用于转移性去势抵抗性前列腺癌。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: 未列出
地点: United States
申办方: University of Oklahoma Health Sciences Center

正在招募 Phase 1

NCI NCT06305598 / NCI-2024-01390

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients with Metastatic Castration Resistant Prostate Cancer

AI 简述这是一项I期试验，研究双极雄激素治疗以恢复转移性去势抵抗性前列腺癌对ADT的敏感性。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: 未列出
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1

NCI NCT06369246 / NCI-2024-03308

Stereotactic Body Radiation Therapy for the Treatment of Patients with Advanced Prostate Cancer, PRORAD-5 Trial

AI 简述这是一项I期试验，研究立体定向体部放疗用于晚期前列腺癌。

?

适用疾病: Stage IIB Prostate Cancer；Stage IIC Prostate Cancer；Stage IIIA Prostate Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT06220864 / NCI-2024-03474

SNV1521 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究SNV1521用于多种晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Metastatic Castration-Resistant Prostate Carcinoma
干预: 未列出
地点: United States
申办方: Synnovation Therapeutics, Inc.

正在招募 Phase 1

NCI NCT06242470 / NCI-2024-04298

A Study of MGC026 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究MGC026用于晚期实体瘤患者，在美国、澳大利亚、英国等地开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: MacroGenics Inc

正在招募 Phase 1

NCI NCT06576037 / NCI-2024-07312

CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin

AI 简述这是一项I期试验，研究CBP-1019联合FOLFOX并用或不用其他药物治疗转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT06636123 / NCI-2024-09343

GZ17-6.02 for the Treatment of Patients with Progressive, Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项I期试验，在美国研究GZ17-6.02用于进展性转移性去势抵抗性前列腺癌。

?

适用疾病: Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Prostate Cancer
干预: 未列出
地点: United States
申办方: VCU Massey Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06551142 / NCI-2024-09382

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

AI 简述这是一项I期试验，研究GSK5764227用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Metastatic Castration-Resistant Prostate Carcinoma
干预: 未列出
地点: United States
申办方: GlaxoSmithKline

正在招募 Phase 1

NCI NCT06710379 / NCI-2025-02183

A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

AI 简述这是一项I期试验，研究ADRX-0405用于晚期实体瘤。在美国开展。

?

适用疾病: Stage III Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Adcentrx Therapeutics

正在招募 Phase 1

NCI NCT06906900 / NCI-2025-02319

Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis

AI 简述这是一项I期试验，研究肿瘤电场治疗用于难治性脊柱转移瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IVB Hepatocellular Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募阶段未标明

NCI NCT06824818 / NCI-2025-03963

Discontinuation of Standard LHRH Agonist Therapy in Elderly Prostate Cancer Patients

AI 简述这是一项试验，研究老年前列腺癌患者停用标准LHRH激动剂治疗，在美国开展。

?

适用疾病: Prostate Cancer
干预: 未列出
地点: United States
申办方: University of Chicago Comprehensive Cancer Center

正在招募阶段未标明

NCI NCT06990542 / NCI-2025-04471

Image Guided Tumor Focused Radiation Therapy compared to Standard Whole Prostate Radiation Therapy for the Treatment of Patients with Intermediate and High-risk Prostate Cancer, RADTARGET Trial

AI 简述这是一项试验，比较图像引导下肿瘤聚焦放疗与标准全前列腺放疗用于中高风险前列腺癌。

?

适用疾病: Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: UC San Diego Moores Cancer Center

正在招募 Phase 1

NCI NCT07054346 / NCI-2025-04497

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 for the Treatment of Prostate Adenocarcinoma, LUTACT Trial

AI 简述这是一项I期试验，比较两种PSMA靶向放射配体用于前列腺腺癌。

?

适用疾病: Stage IIIC Prostate Cancer；Stage IVA Prostate Cancer；Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of California San Francisco

正在招募 Phase 1

NCI NCT06458712 / NCI-2025-05692

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

AI 简述这是一项I期试验，在美国、法国等地研究DSB2455用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage II Pancreatic Cancer；Stage III Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Duke Street Bio Ltd

正在招募 Phase 1

NCI NCT07145177 / NCI-2025-05994

177Lu-PSMA-617 with Liver Directed Therapy for the Treatment of Castration Resistant Prostate Cancer with Liver Metastasis

AI 简述这是一项I期试验，在美国研究177Lu-PSMA-617联合肝脏导向治疗用于前列腺癌肝转移。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma；Metastatic Malignant Neoplasm to the Liver
干预: 未列出
地点: United States
申办方: University of California San Francisco

正在招募 Phase 1

NCI NCT07006727 / NCI-2025-07471

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

AI 简述这是一项I期试验，研究225Ac-ETN029用于DLL3阳性晚期实体瘤，在美国、加拿大、韩国等地开展。

?

适用疾病: Stage III Lung Cancer；Stage IV Lung Cancer；Stage III Prostate Cancer
干预: 未列出
地点: United States
申办方: Novartis Pharmaceuticals Corporation

正在招募 Phase 1

NCI NCT06959706 / NCI-2025-08169

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究TGW101用于晚期实体瘤，包括转移性及局部晚期实体瘤等，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: Tagworks Pharmaceuticals BV

正在招募 Phase 1

NCI NCT07090148 / NCI-2025-09145

pTVG-HP DNA Vaccine + Nivolumab + Targeted Radiation Therapy to Resistant Lesions for the Treatment of Biochemically Recurrent, Oligometastatic Prostate Cancer

AI 简述这是一项I期试验，研究pTVG-HP DNA疫苗联合Nivolumab及靶向放疗用于生化复发寡转移前列腺癌，在美国开展。

?

适用疾病: Stage IVB Prostate Cancer；Biochemically Recurrent Prostate Carcinoma；Oligometastatic Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

正在招募 Phase 1

NCI NCT06130995 / NCI-2026-01048

Relugolix and Enzalutamide for the Treatment of High-Risk Locally Advanced Prostate Cancer

AI 简述这是一项I期试验，研究Relugolix和Enzalutamide用于高危局部晚期前列腺癌。

?

适用疾病: Stage II Prostate Cancer；Stage III Prostate Cancer；Stage IVA Prostate Cancer
干预: 未列出
地点: United States
申办方: University of Oklahoma Health Sciences Center

正在招募阶段未标明

NCI NCT07468903 / NCI-2026-01071

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

AI 简述这是一项试验，研究高剂量率近距离放疗用于早期前列腺癌，在美国开展。

?

适用疾病: Stage I Prostate Cancer；Stage II Prostate Cancer；Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: UCLA / Jonsson Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT05841563 / NCI-2026-03026

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

AI 简述这是一项I期试验，在美国开展，研究PM54用于晚期实体瘤患者。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: PharmaMar SA

正在招募阶段未标明

NCI NCT07548164 / NCI-2026-03277

Irreversible Electroporation Boost Approach versus Standard Radiation Boost for the Treatment of Intermediate Risk Prostate Cancer, IRRADIANT Trial

AI 简述这是一项NA期试验，比较不可逆电穿孔与标准放疗用于中危前列腺癌，在美国开展。

?

适用疾病: Stage IIB Prostate Cancer；Stage IIC Prostate Cancer；Stage IIIA Prostate Cancer
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1

NCI NCT07541573 / NCI-2026-03508

A Camelid Nanobody B7-H3 Tri-Specific Killer Engager (GTB-5550) for the Treatment of Advanced Solid Tumors that Failed Prior Therapy

AI 简述这是一项I期试验，研究GTB-5550用于既往治疗失败的晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Bladder Urothelial Cancer
干预: 未列出
地点: United States
申办方: University of Minnesota/Masonic Cancer Center

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT02971358

Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer

AI 简述这是一项在奥地利开展的试验，研究根治性前列腺切除术用于高危局部晚期和寡转移前列腺癌。

?

适用疾病: Locally Advanced and Metastatic Prostate Cancer
干预: Radical prostatectomy
地点: Austria
申办方: Medical University of Vienna

正在招募 EARLY / Phase 1 药物放疗

ClinicalTrials.gov / NCI NCT03861676 / NCI-2024-07931

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

AI 简述这是一项早期I期试验，研究PSMA PET引导的聚焦近距离放疗用于前列腺癌。

?

适用疾病: Prostate Cancer；Stage I Prostate Cancer；Stage II Prostate Cancer
干预: Focal brachytherapy with PSMA PET imaging，(18F)DCFPyL
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募阶段未标明器械诊断检测放疗

ClinicalTrials.gov NCT04035642

Single-Dose Image-Guided Radiotherapy With Urethral Sparing and DIL Boost for Intermediate-Risk Prostate Cancer (PROSINT II)

AI 简述这是一项非随机试验，研究单次图像引导放疗（IGRT-VMAT/SDRT）用于中危前列腺癌，在葡萄牙开展。

?

适用疾病: Prostate Cancer
干预: IGRT-VMAT / SDRT 24 Gy in 1 fraction，Rectal balloon with air filling，Urethral catheter loaded with beacon transponders，PSMA PET/CT for DIL definition and/or staging where protocol-required
地点: Portugal
申办方: Fundacao Champalimaud

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT04271579

Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)

AI 简述这是一项观察性研究，PSMA PET阳性单侧盆腔病变的早期前列腺癌复发患者行挽救性淋巴结清扫。

?

适用疾病: Prostate Cancer
干预: Salvage Lymphnode dissection
地点: Germany
申办方: Martini-Klinik am UKE GmbH

正在招募阶段未标明放疗

ClinicalTrials.gov NCT04612907

Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

AI 简述这是一项试验，比较中等分割和超低分割放疗用于转移性激素敏感性前列腺癌，在瑞典开展。

?

适用疾病: Prostate Cancer；Radiotherapy Side Effect；Metastatic Cancer
干预: Moderate hypo-fractionation，Ultra-hypo-fractionation
地点: Sweden
申办方: Umeå University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04729114 / NCI-2022-08389

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

AI 简述这是一项I期试验，研究PRL-02注射剂用于晚期前列腺癌，在美国和波多黎各开展。

?

适用疾病: Prostate Cancer；Metastatic Castration Resistant Prostate Cancer；Metastatic Castration-sensitive Prostate Cancer
干预: PRL-02 injection，prednisone，dexamethasone，enzalutamide
地点: United States，Puerto Rico
申办方: Astellas Pharma Global Development, Inc.

正在招募阶段未标明放疗

ClinicalTrials.gov NCT04838899

Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

AI 简述这是一项试验，研究立体定向消融放疗用于阿比特龙耐药寡进展转移性前列腺癌。

?

适用疾病: Oligoprogressive；Castration-Resistant Prostate Cancer
干预: Stereotactic Body Radiation Therapy (SABR)
地点: Canada
申办方: Sunnybrook Health Sciences Centre

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04886986

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

AI 简述这是一项I期试验，研究225Ac-J591联合177Lu-PSMA小分子用于转移性去势抵抗性前列腺癌。

?

适用疾病: Prostate Cancer
干预: 225Ac-J591，177Lu-PSMA-617，68Ga-PSMA-11，177Lu-PSMA-I&T
地点: United States
申办方: Weill Medical College of Cornell University

正在招募阶段未标明联合产品放疗

ClinicalTrials.gov NCT04983095

Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer

AI 简述这是一项试验，研究立体定向体部放疗用于寡转移激素敏感性前列腺癌。

?

适用疾病: Prostate Cancer Metastatic；Radiation Therapy；Positron-Emission Tomography
干预: stereotactic body radiotherapy，androgen deprivation therapy，Radiotherapy
地点: Sweden
申办方: Karin Soderkvist

正在招募 EARLY / Phase 1 Dietary_Supplement其他手术/操作

ClinicalTrials.gov / NCI NCT05045066 / NCI-2021-08987

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

AI 简述这是一项早期I期试验，研究维生素D补充用于前列腺癌患者。

?

适用疾病: Localized Prostate Carcinoma；Stage IV Prostate Cancer AJCC v8；Locally Recurrent Prostate Carcinoma
干预: Cholecalciferol，Quality-of-Life Assessment，Biospecimen Collection
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05104515

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

AI 简述这是一项I期试验，研究OVM-200作为治疗性癌症疫苗用于前列腺癌、非小细胞肺癌、卵巢癌。

?

适用疾病: Prostate Cancer；Non Small Cell Lung Cancer；Ovarian Cancer
干预: OVM-200
地点: United Kingdom
申办方: Oxford Vacmedix UK Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05107674 / NCI-2023-00784

A Study of NX-1607 in Adults With Advanced Malignancies

AI 简述这是一项I期试验，研究NX-1607用于晚期恶性肿瘤。

?

适用疾病: Ovarian Cancer, Epithelial；Gastric Cancer；GastroEsophageal Junction (GEJ) Cancer
干预: NX-1607，Paclitaxel
地点: United States，United Kingdom
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05176483 / NCI-2022-05617

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

AI 简述这是一项I期试验，研究Zanzalintinib联合免疫药物用于实体瘤，在多国开展。

?

适用疾病: Renal Cell Carcinoma (RCC)；Metastatic Castration-Resistant Prostate Cancer (mCRPC)；Urothelial Carcinoma (UC)
干预: Zanzalintinib，Nivolumab，Ipilimumab，Nivolumab + Relatlimab
地点: United States，Australia，Austria，Belgium 等 9 个
申办方: Exelixis

正在招募阶段未标明放疗

ClinicalTrials.gov NCT05209243

START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC

AI 简述这是一项试验，研究立体定向体部放疗联合雄激素受体治疗用于转移性激素敏感性前列腺癌，在西班牙开展。

?

适用疾病: Prostate Cancer；Stereotactic Body Radiation Therapy
干预: SBRT，STANDARD OF CARE
地点: Spain
申办方: Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05283330 / NCI-2022-07733

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

AI 简述这是一项I期试验，研究²¹²Pb-DOTAM-GRPR1用于GRPR阳性的复发或转移性实体瘤。

?

适用疾病: Cervical Cancer；Breast Cancer；Colon Cancer
干预: ²¹²Pb-DOTAM-GRPR1
地点: United States
申办方: Orano Med Theranostics, SAS

正在招募阶段未标明放疗

ClinicalTrials.gov NCT05328505

Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer

AI 简述这是一项研究，图像引导放疗用于前列腺癌的剂量递增和降级，在加拿大开展。

?

适用疾病: Prostate Cancer
干预: Image-guided Radiotherapy
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05413421 / NCI-2022-05394

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

AI 简述这是一项I期试验，研究ORIC-944单药或联合用药用于转移性前列腺癌。

?

适用疾病: Metastatic Prostate Cancer；Stage IVB Prostate Cancer
干预: ORIC-944，Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets，Apalutamide (Erleada™) 60 mg or 240 mg tablets，Darolutamide (Nubeqa®) 300 mg tablets
地点: United States，Australia，Spain，United Kingdom
申办方: ORIC Pharmaceuticals

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05519449 / NCI-2022-07604

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

AI 简述这是一项I期试验，研究JANX007用于转移性去势抵抗性前列腺癌，在美国和澳大利亚开展。

?

适用疾病: Prostate Cancer；Metastatic Castration-resistant Prostate Cancer；Castration Resistant Prostatic Cancer
干预: JANX007，Darolutamide
地点: United States，Australia
申办方: Janux Therapeutics

正在招募阶段未标明药物手术/操作

ClinicalTrials.gov NCT05649943

Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment

AI 简述这是一项在意大利开展的试验，APA联合ADT对比APA-ADT及局部治疗用于转移性激素敏感性前列腺癌。

?

适用疾病: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
干预: APA + ADT，Local Treatmetn RT or RP
地点: Italy
申办方: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05800665 / NCI-2024-00185

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

AI 简述这是一项I期试验，研究RO7656594用于晚期或转移性前列腺癌，在美国、澳大利亚等国开展。

?

适用疾病: Advanced Prostate Cancer；Metastatic Prostate Cancer；Stage IVB Prostate Cancer
干预: RO7656594
地点: United States，Australia，Canada，France 等 3 个
申办方: Genentech, Inc.

正在招募 Phase 1 生物制剂手术/操作放疗

ClinicalTrials.gov / NCI NCT05805371 / NCI-2023-02186

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项I期试验，研究PSCA靶向CAR-T细胞联合或不联合放疗用于转移性去势抵抗性前列腺癌。

?

适用疾病: Castration-Resistant Prostate Carcinoma；Metastatic Prostate Carcinoma；Stage IVB Prostate Cancer AJCC v8
干预: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes，Biopsy，Biospecimen Collection，Bone Scan
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05818683 / NCI-2024-08549

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

AI 简述这是一项I期试验，研究Pasritamig联合其他药物用于转移性前列腺癌。在美国、澳大利亚、西班牙等地开展。

?

适用疾病: Metastatic Castration-resistant Prostate Neoplasms；Metastatic Hormone-sensitive Prostate Cancer；Stage IVB Prostate Cancer
干预: Pasritamig，Cetrelimab，Cabazitaxel，Docetaxel
地点: United States，Australia，Spain
申办方: Janssen Research & Development, LLC

正在招募阶段未标明放疗

ClinicalTrials.gov NCT05936736

24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer

AI 简述这是一项试验，研究24Gy单次立体定向放疗用于局限性前列腺癌，在意大利开展。

?

适用疾病: Localized Prostate Carcinoma
干预: prostate SBRT
地点: Italy
申办方: IRCCS San Raffaele

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05983432 / NCI-2023-10398

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

AI 简述这是一项I期试验，研究BL-B01D1用于转移性或不可切除非小细胞肺癌及其他实体瘤，在美国、法国等地开展。

?

适用疾病: Non Small Cell Lung Cancer；Lung Cancer；Breast Cancer
干预: BL-B01D1
地点: United States，France，Italy，Japan 等 1 个
申办方: SystImmune Inc.

正在招募 Phase 1 联合产品药物

ClinicalTrials.gov / NCI NCT05997615 / NCI-2025-06539

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

AI 简述这是一项I期试验，研究VIR-5500用于转移性去势抵抗性前列腺癌，在美国、澳大利亚、西班牙、英国等地开展。

?

适用疾病: Hormone-refractory Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: VIR-5500，ARSI
地点: United States，Australia，Spain，United Kingdom
申办方: Vir Biotechnology, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06044857 / NCI-2024-00761

PSMA PET Response Guided SabR in High Risk Pca

AI 简述这是一项I期试验，研究PSMA PET引导的立体定向放疗用于高风险III期前列腺癌。在美国开展。

?

适用疾病: Prostate Adenocarcinoma；Stage III Prostate Cancer
干预: 68-Ga PSMA11
地点: United States
申办方: University of Texas Southwestern Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06046040 / NCI-2024-04859

TmPSMA-02 in mCRPC

AI 简述这是一项1期试验，研究TmPSMA-02 CAR-T细胞用于转移性去势抵抗性前列腺癌。在美国开展。

?

适用疾病: Metastatic Castrate-Resistant Prostate Cancer (mCRPC)；Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer
干预: TmPSMA-02 CAR T Cells
地点: United States
申办方: University of Pennsylvania

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06067841 / NCI-2023-09812

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

AI 简述这是一项I期试验，研究BMS-986460用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Castration-Resistant Prostate Cancer；Prostate Adenocarcinoma
干预: BMS-986460
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06095089 / NCI-2023-09674

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

AI 简述这是一项I期试验，研究JNJ-87189401联合JNJ-78278343用于晚期前列腺癌。

?

适用疾病: Prostatic Neoplasms；Stage III Prostate Cancer；Stage IV Prostate Cancer
干预: JNJ-78278343，JNJ-87189401，Apalutamide，Lutetium Lu-177 Vipivotide Tetraxetan
地点: United States，Australia，France，Japan
申办方: Janssen Research & Development, LLC

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT06193486 / NCI-2024-00992

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

AI 简述这是一项I期试验，研究MSGV1-PSCA-8T28Z用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer
干预: MSGV1-PSCA-8T28Z，Fludarabine，Cyclophosphamide
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06217822

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

AI 简述这是一项I期试验，研究225Ac-PSMA-Trillium用于晚期转移性去势抵抗性前列腺癌。

?

适用疾病: Advanced Metastatic Castration-resistant Prostate Cancer；Prostate Specific Membrane Antigen (PSMA) Expression
干预: 225Ac-PSMA-Trillium (BAY3563254)
地点: United States，Belgium，Canada，Finland 等 6 个
申办方: Bayer

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06343038

Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study

AI 简述这是一项I期试验，研究161Tb-SibuDAB用于转移性去势抵抗性前列腺癌的靶向放射性核素治疗，在瑞士开展。

?

适用疾病: Castration-resistant Prostate Cancer
干预: Injection, 161Tb-SibuDAB,1GBq，Injection, 177Lu-PSMA-I&T, 1GBq，Injection, 161Tb-SibuDAB, Dose Escalation
地点: Switzerland
申办方: University Hospital, Basel, Switzerland

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06440005

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究AGX101用于晚期实体瘤。

?

适用疾病: Cancer；Advanced Cancer；Locally Advanced Carcinoma
干预: AGX101
地点: United States
申办方: Angiex, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06441994

Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer

AI 简述这是一项I期试验，研究靶向α疗法[At-211]PSMA-5用于前列腺癌。

?

适用疾病: Prostate Cancer
干预: PSW-1025
地点: Japan
申办方: Osaka University

正在招募阶段未标明放疗

ClinicalTrials.gov NCT06462963

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

AI 简述这是一项在比利时、意大利、荷兰、瑞士等地开展的试验，比较单次与多次SBRT用于寡转移性乳腺癌、前列腺癌、非小细胞肺癌、结直肠癌。

?

适用疾病: Breast Cancer；Prostate Cancer；NSCLC
干预: single-fraction SBRT，multiple-fraction SBRT
地点: Belgium，Italy，Netherlands，Switzerland
申办方: European Organisation for Research and Treatment of Cancer - EORTC

正在招募阶段未标明放疗

ClinicalTrials.gov NCT06508567

Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era

AI 简述这是一项非随机试验，研究MR引导的高剂量率近距离治疗用于前列腺癌放疗后复发。

?

适用疾病: Prostate Cancer Recurrent；Prostate Cancer
干预: High Dose Rate Brachytherapy
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06531499 / NCI-2025-00996

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

AI 简述这是一项I期试验，研究177Lu-Vipivotide Tetraxetan用于未经化疗的转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: AAA617，Gonadotropin-releasing hormone (GnRH) analogues，Gonadotropin-releasing hormone (GnRH) antagonists
地点: United States，Germany，Netherlands，Spain 等 2 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06582017 / NCI-2024-07730

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

AI 简述这是一项I期试验，研究QXL138AM用于实体瘤和多发性骨髓瘤。在美国开展。

?

适用疾病: Ovarian Cancer；Pancreas Cancer；Urothelial Carcinoma
干预: QXL138AM Injection every 2 weeks by IV Infusion
地点: United States
申办方: Nammi Therapeutics Inc

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06705686 / NCI-2025-06108

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

AI 简述这是一项I期试验，研究新型ACK1抑制剂(R)-9b用于转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer (CRPC)；Metastatic Castration-resistant Prostate Carcinoma；Stage IVB Prostate Cancer
干预: (R)-9bMS
地点: United States
申办方: TechnoGenesys, Inc.

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06776172

Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.

AI 简述这是一项在瑞士开展的试验，比较扩大与不做盆腔淋巴结清扫用于前列腺癌手术。

?

适用疾病: Prostate Cancer Surgery；Prostate Cancers
干预: Extended Pelvic Lymph Node Dissection
地点: Switzerland
申办方: University Hospital, Basel, Switzerland

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06778863

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

AI 简述这是一项I期试验，研究CLSP-1025用于p53 R175H突变实体瘤。

?

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Metastatic Solid Tumor
干预: CLSP-1025
地点: United States
申办方: Clasp Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06784193 / NCI-2025-05945

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究OP-3136用于晚期或转移性实体瘤，包括ER+HER2-乳腺癌、非小细胞肺癌和前列腺癌，在美国和澳大利亚开展。

?

适用疾病: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)；Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)；Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
干预: OP-3136，Fulvestrant，Palazestrant
地点: United States，Australia
申办方: Olema Pharmaceuticals, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06801236 / NCI-2025-01984

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项I期试验，研究ACE-232用于转移性去势抵抗性前列腺癌。

?

适用疾病: Prostate Cancer (Adenocarcinoma)；mCRPC (Metastatic Castration-resistant Prostate Cancer)；Stage IVB Prostate Cancer
干预: ACE-232 tablets
地点: United States
申办方: Acerand Therapeutics (Hong Kong) Limited

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06826768 / NCI-2025-01092

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

AI 简述这是一项I期试验，研究REGN5678加Cemiplimab用于转移性去势抵抗性前列腺癌。

?

适用疾病: Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma
干预: REGN5678，Cemiplimab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06830850

A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

AI 简述这是一项I期试验，研究HRS-5041用于转移性去势抵抗性前列腺癌患者。

?

适用疾病: Metastatic Castration Resistant Prostate Cancer
干预: HRS-5041 Single dose of HRS-5041 orally administered
地点: Australia
申办方: Atridia Pty Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06879041 / NCI-2025-05384

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项I期试验，研究[225Ac]-AZD2284用于转移性去势抵抗性前列腺癌，在美国、澳大利亚、南非等地开展。

?

适用疾病: Metastatic Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Prostate Neuroendocrine Carcinoma
干预: AZD2287，AZD2275，AZD2284
地点: United States，Australia，South Africa
申办方: AstraZeneca

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06910657

IDOV-Immune for Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDOV-Immune用于晚期实体瘤，包括结直肠癌、胰腺癌等。在美国和澳大利亚开展。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Melanoma
干预: IDOV-Immune (oncolytic vaccinia virus)
地点: United States，Australia
申办方: ViroMissile, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06943495

Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)

AI 简述这是一项1期试验，研究个体化对比固定剂量177Lu-PSMA-617用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
干预: 177Lu-PSMA-617，177Lu-PSMA-617
地点: Canada
申办方: Jean-Mathieu Beauregard

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06966024 / NCI-2025-06668

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

AI 简述这是一项I期试验，研究DCC-2812用于晚期泌尿生殖系统癌症。

?

适用疾病: Renal Cell Carcinoma；Urothelial Carcinoma；Castration-resistant Prostate Cancer
干预: DCC-2812
地点: United States
申办方: Deciphera Pharmaceuticals, LLC

正在招募阶段未标明放疗

ClinicalTrials.gov NCT06978296

HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS)

AI 简述这是一项试验，研究立体定向放射治疗用于转移性前列腺癌的骨和淋巴结转移，在法国开展。

?

适用疾病: Prostate Cancer Metastatic Disease；Oligometastatic Prostate Cancer (OMPC)
干预: Stereotactic body radiotherapy (SBRT)
地点: France
申办方: Institut Cancerologie de l'Ouest

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06999187 / NCI-2025-07429

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

AI 简述这是一项I期试验，研究DR-0202用于晚期复发难治性癌，在美国开展。

?

适用疾病: Triple Negative Breast Cancer；HER2-negative Breast Cancer；Non Small Cell Lung Cancer
干预: DR-0202
地点: United States
申办方: Dren Bio

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07080242 / NCI-2025-09219

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

AI 简述这是一项I期试验，在美国研究BL-M14D1用于局部晚期或转移性小细胞肺癌和神经内分泌肿瘤。

?

适用疾病: Small Cell Lung Cancer Metastatic or Locally Advanced；Neuroendocrine Cancer；Metastatic Neuroendocrine Prostate Cancer
干预: BL-M14D1
地点: United States
申办方: SystImmune Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07082920 / NCI-2025-06705

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

AI 简述这是一项I期试验，研究JNJ-78278343联合JNJ-95298177用于前列腺癌，在美国、英国开展。

?

适用疾病: Prostatic Neoplasms；Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Adenocarcinoma
干预: JNJ-78278343，JNJ-95298177
地点: United States，United Kingdom
申办方: Janssen Research & Development, LLC

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07103018 / NCI-2025-09721

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

AI 简述这是一项I期试验，研究KTX-2001用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Metastatic Castration-Resistant Prostate Cancer Patients；Metastatic Castration-resistant Prostate Cancer, mCRPC
干预: KTX-2001，KTX-2001 + Darolutamide (NUBEQA®)
地点: United States
申办方: K36 Therapeutics, Inc.

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT07129551

Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery

AI 简述这是一项观察性试验，在德国研究术前及术后3D模型对PSMA靶向手术效果的影响。

?

适用疾病: Prostate Cancer (Adenocarcinoma)
干预: preop virtual 3D model，postop 3D model
地点: Germany
申办方: Martini-Klinik am UKE GmbH

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07140900 / NCI-2025-06740

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

AI 简述这是一项I期试验，在美国、澳大利亚、瑞士等地开展，研究Xaluritamig联合雄激素受体通路抑制剂用于转移性激素敏感性前列腺癌。

?

适用疾病: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)；Stage IVB Prostate Cancer；Metastatic Castration-Sensitive Prostate Carcinoma
干预: Xaluritamig，Darolutamide，Abiraterone
地点: United States，Australia，Switzerland
申办方: Amgen

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07189403 / NCI-2026-01322

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

AI 简述这是一项I期试验，研究DS9051b用于晚期或转移性肾上腺皮质癌和转移性去势抵抗性前列腺癌，在美国、法国、英国等地开展。

?

适用疾病: Advanced or Metastatic Adrenocortical Carcinoma；Metastatic Castration-resistant Prostate Cancer；Stage IV Prostate Cancer
干预: DS9051b
地点: United States，France，United Kingdom
申办方: Daiichi Sankyo

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07219147 / NCI-2025-07470

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项I期试验，研究177Lu-PSMA-617联合Sipuleucel-T用于转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Metastatic Castration-Resistant Prostate Adenocarcinoma；Stage IVB Prostate Cancer AJCC v8；Stage IVB Prostate Cancer
干预: Biospecimen Collection，Bone Scan，Computed Tomography，Leukapheresis
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07424547

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究SYS6043用于晚期/转移性实体瘤。

?

适用疾病: Cancer；Solid Tumor Cancer；Advanced Metastatic Cancer
干预: SYS6043
地点: United States
申办方: Conjupro Biotherapeutics, Inc.

正在招募阶段未标明药物放疗

ClinicalTrials.gov NCT07483658

Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

AI 简述这是一项非劣效性试验，比较两种分割方案（62.5 Gy/25次 vs 52.5 Gy/20次）的挽救性盆腔放疗用于术后复发前列腺癌。

?

适用疾病: Reccurent/Metastatic Solid Tumor Disease；Prostate Cancer (Post Prostatectomy)；Prostate Cancer
干预: Standard Fractionation Post-Operative Salvage Radiotherapy (25 fractions)，Hypofractionated Post-Operative Salvage Radiotherapy (20 fractions)，Androgen Deprivation Therapy (ADT)
地点: Canada
申办方: CHU de Quebec-Universite Laval

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07493512

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

AI 简述这是一项I期试验，研究Xaluritamig用于转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)
干预: Xaluritamig
地点: United States
申办方: Amgen

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07503808 / NCI-2026-03006

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

AI 简述这是一项I期试验，研究IDE034用于局部晚期或转移性实体瘤成人患者。

?

适用疾病: Esophageal Squamous Cell Carcinoma；High Grade Serous Ovarian Cancer；Head and Neck Squamous Cell Carcinoma
干预: IDE034
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07540572

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDE574联合Fulvestrant用于多种晚期实体瘤，在美国开展。

?

适用疾病: ER+, HER 2- Breast Cancer；Non-small Cell Lung Cancer (NSCLC)；Castration-resistant Prostate Cancer (CRPC)
干预: IDE574，Fulvestrant injection
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 基因治疗

ClinicalTrials.gov NCT07543055

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

AI 简述这是一项I期试验，研究BPX-601 CAR T细胞用于转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Prostate Cancer
干预: BPX-601
地点: United States
申办方: Regeneron Pharmaceuticals

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07545811

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项I期试验，研究JANX014用于转移性去势抵抗性前列腺癌。

?

适用疾病: Prostate Cancer；Metastatic Castration-resistant Prostate Cancer；Castration-resistant Prostate Cancer
干预: JANX014
地点: United States
申办方: Janux Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07570979

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

AI 简述这是一项I期试验，研究口服INR731单药或联合ARPI用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)
干预: INR731，Enzalutamide，Abiraterone，Androgen deprivation therapy (ADT)
地点: United States，Australia
申办方: Novartis Pharmaceuticals

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT07580196

Bilateral Versus Unilateral Lymph Node Dissection in High-Risk Prostate Cancer (BALANCE)

AI 简述这是一项比较双侧与单侧淋巴结清扫用于高危前列腺癌的试验，在意大利开展。

?

适用疾病: Prostate Cancer
干预: Unilateral Extended Pelvic Lymph Node Dissection，Bilateral Extended Pelvic Lymph Node Dissection
地点: Italy
申办方: University of Turin, Italy

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07581184

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项I期试验，研究[225Ac]Ac-AKY-2519用于转移性去势抵抗性前列腺癌。

?

适用疾病: Castration Resistant Metastatic Prostate Cancer；Prostate Cancer；mCRPC (Metastatic Castration-resistant Prostate Cancer)
干预: [225Ac]Ac-AKY-2519 (therapeutic)，[64Cu]Cu-AKY-2519 (imaging)
地点: United States
申办方: Aktis Oncology, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07621692

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

AI 简述这是一项I期试验，研究161Tb-PSMA-I&T用于转移性去势抵抗性前列腺癌，在台湾开展。

?

适用疾病: Metastatic Castration Resistant Prostate Cancer (mCRPC)
干预: 161Tb-PSMA-I&T
地点: Taiwan
申办方: National Taiwan University Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT01913106

HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

AI 简述这是一项1/2期试验，研究HSV-tk+伐昔洛韦联合近距离放疗用于复发性前列腺癌，在美国开展。

?

适用疾病: Prostatic Neoplasms
干预: HSV-tk +Valacyclovir in Combination with Brachytherapy
地点: United States
申办方: The Methodist Hospital Research Institute

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04104607

The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma

AI 简述这是一项I期试验，研究PSMAxCD3双特异性抗体CC-1用于去势抵抗前列腺癌。

?

适用疾病: Castration-Resistant Prostatic Cancer
干预: CC-1, PSMAxCD3
地点: Germany
申办方: University Hospital Tuebingen

正在招募 Phase 1 药物放疗

ClinicalTrials.gov / NCI NCT04235777 / NCI-2020-00580

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

AI 简述这是一项I期试验，研究M7824联合立体定向放疗和PDS01ADC用于转移性非前列腺泌尿生殖系统肿瘤。

?

适用疾病: Urothelial Cancer；Bladder Cancer；Genitourinary Cancer
干预: Stereotactic body radiation therapy (SBRT)，PDS01ADC，M7824
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05743621

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项I期试验，研究TVB-2640联合恩扎卢胺用于转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Prostatic Neoplasms, Castration-Resistant
干预: TVB-2640，Enzalutamide
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07258407

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

AI 简述这是一项I/II期试验，研究TD001用于PSMA阳性转移性前列腺癌，在美国、澳大利亚等地开展。

?

适用疾病: Metastatic Castration-Resistant Prostatic Cancer
干预: TD001
地点: United States，Australia，Canada，France 等 1 个
申办方: T.O.A.D. Oncology SA

暂时不招募 Phase 2, Phase 3

NCI NCT03456843 / NCI-2018-00047

Surgical Removal of Prostate Tumor and Antiandrogen Therapy with or without Docetaxel in Treating Men with Newly Diagnosed Metastatic Prostate Cancer

AI 简述这是一项II/III期试验，比较手术联合抗雄激素治疗加或不加多西他赛用于新诊断转移性前列腺癌。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Prostatic Adenocarcinoma
干预: 未列出
地点: United States，Japan，Australia，Hong Kong 等 2 个
申办方: Yale University

暂时不招募 Phase 3

NCI NCT04981834 / NCI-2021-05989

Robot-Assisted Radical Prostatectomy with or without Vesicopexy in Patients with Prostate Cancer

AI 简述这是一项III期试验，比较机器人前列腺切除术伴或不伴膀胱固定术用于前列腺癌。

?

适用疾病: Stage I Prostate Cancer；Stage II Prostate Cancer；Stage III Prostate Cancer
干预: 未列出
地点: United States
申办方: USC / Norris Comprehensive Cancer Center

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07632690

QLC5508 in Participants With Metastatic Prostate Cancer

AI 简述这是一项III期试验，比较QLC5508与Docetaxel用于转移性前列腺癌。

?

适用疾病: Prostate Cancer
干预: QLC5508，Docetaxel
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

暂时不招募 Phase 1, Phase 2

NCI NCT03217747 / NCI-2018-01118

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients with Advanced Malignancies

AI 简述这是一项I/II期试验，研究Avelumab、Utomilumab、抗OX40抗体和放疗用于晚期恶性肿瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1, Phase 2

NCI NCT03131908 / NCI-2018-01609

PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Patients with Stage III-IV Cancer and PTEN Loss

AI 简述这是一项I/II期试验，研究PI3K-beta抑制剂GSK2636771联合Pembrolizumab用于PTEN缺失的III-IV期癌症，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Stage III Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT03970382 / NCI-2019-03772

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究基因编辑的TCR T细胞联合或不联合抗PD-1用于多种实体瘤。在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: PACT Pharma, Inc.

暂时不招募 Phase 1, Phase 2

NCI NCT04071236 / NCI-2019-05620

Radiation Medication (Radium-223 dichloride) versus Radium-223 dichloride plus Radiation Enhancing Medication (M3814) versus Radium-223 dichloride plus M3814 plus Avelumab (a type of immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

AI 简述这是一项I/II期试验，研究镭-223联合或不联合M3814及avelumab用于去势抵抗性前列腺癌骨转移。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Carcinoma；Metastatic Malignant Neoplasm to the Bone
干预: 未列出
地点: United States
申办方: Yale University Cancer Center LAO

暂时不招募 Phase 1, Phase 2

NCI NCT05036226 / NCI-2022-03007

Autophagy Therapeutics (Hydroxychloroquine, Nelfinavir, Metformin, Dasatinib, and Sirolimus) for the Treatment of Advanced Solid Tumors or Relapsed Prostate Cancer

AI 简述这是一项I/II期试验，研究多种自噬治疗药物用于晚期实体瘤或复发前列腺癌。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Prostate Cancer；Stage IV Prostate Cancer
干预: 未列出
地点: United States
申办方: Medical University of South Carolina

暂时不招募 Phase 2

NCI NCT05445609 / NCI-2022-05290

Vidutolimod (CMP-001) in Combination with Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

AI 简述这是一项II期试验，研究Vidutolimod联合纳武利尤单抗用于转移性去势抵抗性前列腺癌。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Prostatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: Emory University Hospital/Winship Cancer Institute

暂时不招募 Phase 2

NCI NCT05361915 / NCI-2022-09673

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

AI 简述这是一项II期试验，研究Abivertinib联合Abiraterone用于转移性去势抵抗性前列腺癌，在美国开展。

?

适用疾病: Castration-Resistant Prostate Cancer；Stage IVB Prostate Cancer；Metastatic Prostate Cancer
干预: 未列出
地点: United States
申办方: Sorrento Therapeutics, Inc.

暂时不招募 Phase 1

NCI NCT05613894 / NCI-2023-02087

Cabozantinib in Combination with Lutetium-177 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, CaboLu Study

AI 简述这是一项I期试验，研究Cabozantinib联合Lutetium-177用于转移性去势抵抗性前列腺癌。

?

适用疾病: Stage IVB Prostate Cancer；Metastatic Castration-Resistant Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: Huntsman Cancer Institute/University of Utah

暂时不招募 Phase 1, Phase 2

NCI NCT06066437 / NCI-2023-08252

Evaluation of 177Lu rhPSMA-10.1 and Degarelix before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer, Nautilus Trial

AI 简述这是一项I/II期试验，研究177Lu rhPSMA-10.1和Degarelix用于高危局限期前列腺癌根治术前治疗。在美国开展。

?

适用疾病: Stage IIIB Prostate Cancer；Stage IIIC Prostate Cancer；Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 2

NCI NCT06173362 / NCI-2023-09814

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

AI 简述这是一项II期试验，研究阿比特龙联合泼尼松或Darolutamide用于晚期前列腺癌。

?

适用疾病: Stage III Prostate Cancer；Stage IV Prostate Cancer；Advanced Prostate Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of California Davis Comprehensive Cancer Center

即将招募 Phase 1 药物放疗

ClinicalTrials.gov NCT07090369

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

AI 简述这是一项I期试验，研究177Lu-PSMA-I&T联合Olaparib和Pembrolizumab用于转移性去势抵抗性前列腺癌，在澳大利亚开展。

?

适用疾病: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
干预: Olaparib (300 mg BID)，Pembrolizumab，177Lu-PSMA-I&T
地点: Australia
申办方: Peter MacCallum Cancer Centre, Australia

即将招募 Phase 1 药物放疗

ClinicalTrials.gov NCT07316686

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

AI 简述这是一项I期试验，研究多西他赛联合177Lu-PSMA-I&T用于一线治疗转移性去势抵抗性前列腺腺癌，在巴西开展。

?

适用疾病: Prostate Cancer (Adenocarcinoma)
干预: Docetaxel 50mg/m2，Docetaxel 60mg/m2，Docetaxel 75 mg/m²，177Lu-PSMA-I&T
地点: Brazil
申办方: Instituto do Cancer do Estado de São Paulo

即将招募 EARLY / Phase 1 器械药物

ClinicalTrials.gov NCT07609225

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

AI 简述这是一项早期I期试验，研究化学位移编码MRI用于放射性药物治疗中的活性骨髓剂量测定。在美国开展。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer
干预: 3'-Deoxy-3'-[18F]-fluorothymidine，Chemical-shift-encoded MRI
地点: United States
申办方: University of Wisconsin, Madison

即将招募阶段未标明放疗

ClinicalTrials.gov NCT07635108

MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)

AI 简述这是一项试验，研究MR引导单次SBRT用于结节寡复发前列腺癌，在丹麦开展。

?

适用疾病: Prostate Cancer；Oligo-metastatic Prostate Carcinoma；Oligometastatic Cancer
干预: Single-fraction SBRT
地点: Denmark
申办方: Odense University Hospital

即将招募 EARLY / Phase 1 药物放疗

ClinicalTrials.gov NCT07674771

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

AI 简述这是一项早期1期试验，在美国研究68-Ga PSMA11和放射治疗用于转移性去势敏感性前列腺癌。

?

适用疾病: Castrate Sensitive Prostate Cancer；Prostate Cancer；Metastasis Castration Resistant Prostate Cancer(mCRPC)
干预: Drug: 68-Ga PSMA11，Adaptive stereotactic ablative radiotherapy (SABR)，68Ga-PSMA-11，Adaptive stereotactive ablative radiotherapy (SABR)
地点: United States
申办方: University of Texas Southwestern Medical Center

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05896371

A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy

AI 简述这是一项I/II期试验，研究个体化177Lu-PSMA-I&T用于前列腺癌。

?

适用疾病: Cancer；Prostate Cancer；Metastatic Cancer
干预: 177Lu-PSMA-I&T - escalating renal absorbed dose，177Lu-PSMA-I&T - recommended phase 2 regime
地点: 未列出
申办方: CHU de Quebec-Universite Laval

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06827080

Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项I/II期试验，研究161Tb-NYM032用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer, MCRPC；Cancer
干预: 30 mCi NYMO32，50 mCi NYMO32，80 mCi NYMO32，130 mCi NYMO32
地点: 未列出
申办方: Zhengguo Chen

即将招募 Phase 1 药物

ClinicalTrials.gov NCT06866795

Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)

AI 简述这是一项I期试验，研究GT-220F用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration Resistant Prostate Cancer
干预: GT-220F capsule
地点: 未列出
申办方: Geode Therapeutics Inc.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06890832

A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer

AI 简述这是一项II期试验，研究不同剂量口服Cabazitaxel片用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer, MCRPC
干预: 50 mg cabazitaxel，100 mg cabazitaxel，200 mg cabazitaxel
地点: 未列出
申办方: Jina Pharmaceuticals Inc.

即将招募 Phase 1 手术/操作放疗

ClinicalTrials.gov NCT06982222

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

AI 简述这是一项I期试验，研究Sn-117m-DTPA用于晚期骨转移癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Metastatic Lung Non-Small Cell Carcinoma
干预: Biospecimen Collection，Bone Scan，Computed Tomography，Positron Emission Tomography
地点: 未列出
申办方: National Cancer Institute (NCI)

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07164794

Memantine Hydrochloride in Prostate Cancer Patients

AI 简述这是一项II期试验，研究美金刚用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)；Prostate Cancer；Neuroendocrine Prostate Cancer (NEPC)
干预: Memantine Hydrochloride
地点: 未列出
申办方: Bin Xu

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07244393

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项1期试验，研究Lutetium (177Lu) DGUL联合Pembrolizumab用于转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)
干预: Lutetium (177Lu) DGUL，Pembrolizumab
地点: 未列出
申办方: Cellbion Co., Ltd.

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07310355

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

AI 简述这是一项I/II期试验，研究68Ga-PSMA-0057和177Lu-PSMA-0057用于PSMA阳性转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer (mCRPC)
干预: 68Ga-PSMA-0057，177Lu-PSMA-0057
地点: 未列出
申办方: Chengdu StarRay Therapeutics Co., Ltd

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07415135

Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy

AI 简述这是一项II期试验，研究DGPR1008用于前列腺癌机器人根治术中的术中成像。

?

适用疾病: Prostate Cancer
干预: 0.02 mg/kg of DGPR1008 Injection was administered 24 hours before surgery，0.04 mg/kg of DGPR1008 Injection was administered 24 hours before surgery，0.06 mg/kg of DGPR1008 Injection was administered 24 hours before surgery
地点: 未列出
申办方: Zhu Yinjie

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07423117

A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

AI 简述这是一项I期试验，研究ITC-6146RO用于标准治疗失败的晚期或转移性实体瘤。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Non-small Cell Lung Cancer；Triple Negative Breast Cancer
干预: ITC-6146RO
地点: 未列出
申办方: IntoCell, Inc

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07592910

A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

AI 简述这是一项II期试验，研究Mevrometostat联合恩扎卢胺用于既往接受ARPI治疗的转移性去势抵抗性前列腺癌。

?

适用疾病: Metastatic Castrate Resistant Prostate Cancer (mCRPC)；Prostate Cancer (Adenocarcinoma)
干预: Mevrometostat，Enzalutamide
地点: 未列出
申办方: Prostate Cancer Clinical Trials Consortium

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07594106

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

AI 简述这是一项I/II期试验，研究REGN15505单药或联合Cemiplimab或REGN4336用于转移性去势抵抗性前列腺癌和透明细胞肾细胞癌。

?

适用疾病: Metastatic Castration-Resistant Prostate Cancer (mCRPC)；Clear Cell Renal Cell Carcinoma (ccRCC)
干预: REGN15505，REGN15505+Cemiplimab，REGN15505+REGN4336
地点: 未列出
申办方: Regeneron Pharmaceuticals

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07623460

Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer

AI 简述这是一项II期试验，研究Zanzalintinib用于化疗初治的转移性去势抵抗性前列腺癌。

?

适用疾病: mCRPC (Metastatic Castration-resistant Prostate Cancer)
干预: Zanzalintinib
地点: 未列出
申办方: Stuthi Perimbeti

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07636707

QLF4113 in Participants With Metastatic Prostate Cancer

AI 简述这是一项I期试验，研究QLF4113用于转移性前列腺癌。

?

适用疾病: Prostate Cancer
干预: QLF4113 for injection
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

术语	中文意思	对找临床试验有什么用
mCRPC	转移性去势抵抗性前列腺癌，指在低睾酮状态下仍进展的转移性疾病。	海外前列腺癌试验非常常见的入组类别。
mCSPC	转移性去势敏感性前列腺癌。	和 mCRPC 是不同阶段，搜索和入组条件要区分。
BRCA / HRR mutation	DNA 修复相关基因改变。	可以找 PARP 抑制剂或 DNA repair 相关试验。
PSMA	前列腺特异性膜抗原，是影像和放射性配体治疗的重要靶点。	可以找 PSMA radioligand therapy、PSMA PET 相关试验。
Androgen receptor	雄激素受体通路是前列腺癌治疗核心方向之一。	可以找 AR inhibitor、androgen receptor pathway 相关试验。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

前列腺癌

当前同步到的治疗类试验